<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <!-- AppResources meta begin -->
        <script type="text/javascript">var ncbi_startTime = new Date();</script>
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="">

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="pmc"><meta name="ncbi_pdid" content="article"><meta name="ncbi_acc" content=""><meta name="ncbi_domain" content="nihpa"><meta name="ncbi_report" content="record"><meta name="ncbi_type" content="fulltext"><meta name="ncbi_objectid" content=""><meta name="ncbi_pcid" content="/articles/PMC5367948/"><meta name="ncbi_app" content="pmc">
        <!-- Logger end -->
        
        <title>Association of Liver Injury From Specific Drugs, or Groups of Drugs,
With Polymorphisms in HLA and Other Genes in a Genome-wide Association
Study</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css"><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367948/"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="Gastroenterology"><meta name="citation_title" content="Association of Liver Injury From Specific Drugs, or Groups of Drugs,
With Polymorphisms in HLA and Other Genes in a Genome-wide Association
Study"><meta name="citation_authors" content="Paola Nicoletti, Guruprasad P. Aithal, Einar S. Bjornsson, Raul J. Andrade, Ashley Sawle, Marco Arrese, Huiman X. Barnhart, Emmanuelle Bondon-Guitton, Paul H. Hayashi, Fernando Bessone, Alfonso Carvajal, Ingolf Cascorbi, Elizabeth T. Cirulli, Naga Chalasani, Anita Conforti, Sally A. Coulthard, Mark J. Daly, Christopher P. Day, John F. Dillon, Robert J. Fontana, Jane I. Grove, Pär Hallberg, Nelia Hernández, Luisa Ibáñez, Gerd A. Kullak-Ublick, Tarja Laitinen, Dominique Larrey, M. Isabel Lucena, Anke H. Maitland-van der Zee, Jennifer H. Martin, Mariam Molokhia, Munir Pirmohamed, Elizabeth E. Powell, Shengying Qin, Jose Serrano, Camilla Stephens, Andrew Stolz, Mia Wadelius, Paul B. Watkins, Aris Floratos, Yufeng Shen, Matthew R. Nelson, Thomas J. Urban, Ann K. Daly"><meta name="citation_date" content="April 2017"><meta name="citation_issue" content="5"><meta name="citation_volume" content="152"><meta name="citation_firstpage" content="1078"><meta name="citation_doi" content="10.1053/j.gastro.2016.12.016"><meta name="citation_abstract_html_url" content="/pmc/articles/PMC5367948/?report=abstract"><meta name="citation_pmid" content="28043905"><meta name="DC.Title" content="Association of Liver Injury From Specific Drugs, or Groups of Drugs,
With Polymorphisms in HLA and Other Genes in a Genome-wide Association
Study"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="NIH Public Access"><meta name="DC.Contributor" content="Paola Nicoletti"><meta name="DC.Contributor" content="Guruprasad P. Aithal"><meta name="DC.Contributor" content="Einar S. Bjornsson"><meta name="DC.Contributor" content="Raul J. Andrade"><meta name="DC.Contributor" content="Ashley Sawle"><meta name="DC.Contributor" content="Marco Arrese"><meta name="DC.Contributor" content="Huiman X. Barnhart"><meta name="DC.Contributor" content="Emmanuelle Bondon-Guitton"><meta name="DC.Contributor" content="Paul H. Hayashi"><meta name="DC.Contributor" content="Fernando Bessone"><meta name="DC.Contributor" content="Alfonso Carvajal"><meta name="DC.Contributor" content="Ingolf Cascorbi"><meta name="DC.Contributor" content="Elizabeth T. Cirulli"><meta name="DC.Contributor" content="Naga Chalasani"><meta name="DC.Contributor" content="Anita Conforti"><meta name="DC.Contributor" content="Sally A. Coulthard"><meta name="DC.Contributor" content="Mark J. Daly"><meta name="DC.Contributor" content="Christopher P. Day"><meta name="DC.Contributor" content="John F. Dillon"><meta name="DC.Contributor" content="Robert J. Fontana"><meta name="DC.Contributor" content="Jane I. Grove"><meta name="DC.Contributor" content="Pär Hallberg"><meta name="DC.Contributor" content="Nelia Hernández"><meta name="DC.Contributor" content="Luisa Ibáñez"><meta name="DC.Contributor" content="Gerd A. Kullak-Ublick"><meta name="DC.Contributor" content="Tarja Laitinen"><meta name="DC.Contributor" content="Dominique Larrey"><meta name="DC.Contributor" content="M. Isabel Lucena"><meta name="DC.Contributor" content="Anke H. Maitland-van der Zee"><meta name="DC.Contributor" content="Jennifer H. Martin"><meta name="DC.Contributor" content="Mariam Molokhia"><meta name="DC.Contributor" content="Munir Pirmohamed"><meta name="DC.Contributor" content="Elizabeth E. Powell"><meta name="DC.Contributor" content="Shengying Qin"><meta name="DC.Contributor" content="Jose Serrano"><meta name="DC.Contributor" content="Camilla Stephens"><meta name="DC.Contributor" content="Andrew Stolz"><meta name="DC.Contributor" content="Mia Wadelius"><meta name="DC.Contributor" content="Paul B. Watkins"><meta name="DC.Contributor" content="Aris Floratos"><meta name="DC.Contributor" content="Yufeng Shen"><meta name="DC.Contributor" content="Matthew R. Nelson"><meta name="DC.Contributor" content="Thomas J. Urban"><meta name="DC.Contributor" content="Ann K. Daly"><meta name="DC.Date" content="2017 Apr"><meta name="DC.Identifier" content="10.1053/j.gastro.2016.12.016"><meta name="DC.Language" content="en"><meta property="og:title" content="Association of Liver Injury From Specific Drugs, or Groups of Drugs,
With Polymorphisms in HLA and Other Genes in a Genome-wide Association
Study"><meta property="og:type" content="article"><meta property="og:description" content="We performed a genome-wide association study (GWAS) to identify
genetic risk factors for drug-induced liver injury (DILI) from licensed
drugs without previously reported genetic risk factors.We performed a GWAS of 862 persons with DILI and 10588
population-matched ..."><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367948/"><meta property="og:site_name" content="PubMed Central (PMC)"><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ncbi"><meta name="ncbi_feature" content="associated_data"><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css"><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print"><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/'"><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css"><script type="text/javascript" src="/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js"></script><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-hhspa.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
      </style><meta name="cited_in_systematic_reviews" content=""><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC5367948/epub/"><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC5367948/pdf/nihms-840066.pdf">

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico"><meta name="ncbi_phid" content="CE8AFBBBDD59E73100000000030601C3.m_8">
<meta name="referrer" content="origin-when-cross-origin"><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css"><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print"><script async="1" src="https://www.google-analytics.com/analytics.js"></script><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1px; bottom: 2px; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/mathjax/2.6.1/extensions/MathEvents.js?rev=2.6.1"></script><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/mathjax/2.6.1/extensions/MathZoom.js?rev=2.6.1"></script><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/mathjax/2.6.1/extensions/MathMenu.js?rev=2.6.1"></script><style type="text/css">.MathJax_Hover_Frame {border-radius: .25em; -webkit-border-radius: .25em; -moz-border-radius: .25em; -khtml-border-radius: .25em; box-shadow: 0px 0px 15px #83A; -webkit-box-shadow: 0px 0px 15px #83A; -moz-box-shadow: 0px 0px 15px #83A; -khtml-box-shadow: 0px 0px 15px #83A; border: 1px solid #A6D ! important; display: inline-block; position: absolute}
.MathJax_Menu_Button .MathJax_Hover_Arrow {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 4px; -webkit-border-radius: 4px; -moz-border-radius: 4px; -khtml-border-radius: 4px; font-family: 'Courier New',Courier; font-size: 9px; color: #F0F0F0}
.MathJax_Menu_Button .MathJax_Hover_Arrow span {display: block; background-color: #AAA; border: 1px solid; border-radius: 3px; line-height: 0; padding: 4px}
.MathJax_Hover_Arrow:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_Hover_Arrow:hover span {background-color: #CCC!important}
</style><style type="text/css">#MathJax_Zoom {position: absolute; background-color: #F0F0F0; overflow: auto; display: block; z-index: 301; padding: .5em; border: 1px solid black; margin: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; -webkit-box-sizing: content-box; -moz-box-sizing: content-box; box-sizing: content-box; box-shadow: 5px 5px 15px #AAAAAA; -webkit-box-shadow: 5px 5px 15px #AAAAAA; -moz-box-shadow: 5px 5px 15px #AAAAAA; -khtml-box-shadow: 5px 5px 15px #AAAAAA; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_ZoomOverlay {position: absolute; left: 0; top: 0; z-index: 300; display: inline-block; width: 100%; height: 100%; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
#MathJax_ZoomFrame {position: relative; display: inline-block; height: 0; width: 0}
#MathJax_ZoomEventTrap {position: absolute; left: 0; top: 0; z-index: 302; display: inline-block; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
</style><style type="text/css">#MathJax_About {position: fixed; left: 50%; width: auto; text-align: center; border: 3px outset; padding: 1em 2em; background-color: #DDDDDD; color: black; cursor: default; font-family: message-box; font-size: 120%; font-style: normal; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 15px; -webkit-border-radius: 15px; -moz-border-radius: 15px; -khtml-border-radius: 15px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_About.MathJax_MousePost {outline: none}
.MathJax_Menu {position: absolute; background-color: white; color: black; width: auto; padding: 5px 0px; border: 1px solid #CCCCCC; margin: 0; cursor: default; font: menu; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; -khtml-border-radius: 5px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
.MathJax_MenuItem {padding: 1px 2em; background: transparent}
.MathJax_MenuArrow {position: absolute; right: .5em; padding-top: .25em; color: #666666; font-size: .75em}
.MathJax_MenuActive .MathJax_MenuArrow {color: white}
.MathJax_MenuArrow.RTL {left: .5em; right: auto}
.MathJax_MenuCheck {position: absolute; left: .7em}
.MathJax_MenuCheck.RTL {right: .7em; left: auto}
.MathJax_MenuRadioCheck {position: absolute; left: .7em}
.MathJax_MenuRadioCheck.RTL {right: .7em; left: auto}
.MathJax_MenuLabel {padding: 1px 2em 3px 1.33em; font-style: italic}
.MathJax_MenuRule {border-top: 1px solid #DDDDDD; margin: 4px 3px}
.MathJax_MenuDisabled {color: GrayText}
.MathJax_MenuActive {background-color: #606872; color: white}
.MathJax_MenuDisabled:focus, .MathJax_MenuLabel:focus {background-color: #E8E8E8}
.MathJax_ContextMenu:focus {outline: none}
.MathJax_ContextMenu .MathJax_MenuItem:focus {outline: none}
#MathJax_AboutClose {top: .2em; right: .2em}
.MathJax_Menu .MathJax_MenuClose {top: -10px; left: -10px}
.MathJax_MenuClose {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; font-family: 'Courier New',Courier; font-size: 24px; color: #F0F0F0}
.MathJax_MenuClose span {display: block; background-color: #AAA; border: 1.5px solid; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; line-height: 0; padding: 8px 0 6px}
.MathJax_MenuClose:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_MenuClose:hover span {background-color: #CCC!important}
.MathJax_MenuClose:hover:focus {outline: none}
</style></head>
    <body class="article" id="ui-ncbiexternallink-4"><div id="MathJax_Message" style="display: none;"></div>
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list ui-ncbibasicmenu orientation_hort" id="navcontent" role="menubar"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt" role="presentation"><a class="ui-ncbimenu-link-first" href="/" role="menuitem" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo"></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources" tabindex="-1" role="menuitem">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto" tabindex="-1" role="menuitem">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi" style="top: -0.4em;"><iframe src="https://eutils.ncbi.nlm.nih.gov/entrez/eutils/emyncbi.fcgi?cmd=htmlportal&amp;currenturl=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5367948%2F" style="border:none; height:2.5em; width:40em;" scrolling="no"></iframe></div></div>
                            <div class="header">
    <div class="res_logo">
  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>
  <div class="NLMLogo">
    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>
    <br>
    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>
  </div>
</div>
    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="pubmed" class="last">PubMed</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><div class="jig-ncbiclearbutton-wrap ui-ncbiclearbutton-wrap box-shadow"><input name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'yes'" aria-haspopup="true" aria-autocomplete="list" role="textbox" type="text"><a class="reset" href="#" style="visibility: hidden;"><img src="/core/jig/1.14.8/img/clear.png" alt="Clear input"></a></div></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/pmc/advanced/">Advanced</a>
                    </li><li>
                        <a href="/pmc/journals/">Journal list</a>
                    </li><li class="help">
                        <a target="_blank" href="/books/NBK3825/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <div class="container">
    <div id="maincontent" class="content eight_col col">
        <div class="navlink-box">
            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="article-entrez-filter"><a href="/pmc/?term=hhs%20author%20manuscript[filter]" class="navlink">HHS Author Manuscripts</a></li><li class="accid">PMC5367948</li></ul>
        </div>

        <!-- Journal banner -->
        <div class="pmc-page-banner whole_rhythm"><div><img src="/corehtml/pmc/pmcgifs/logo-hhspa.png" alt="Logo of nihpa" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="0,57,255,75" alt="About Author manuscripts" title="About Author manuscripts" href="https://www.ncbi.nlm.nih.gov/pmc/about/authorms.html" ref="https://www.ncbi.nlm.nih.gov/pmc/about/authorms.html"><area shape="rect" coords="256,57,500,75" alt="Submit a manuscript" title="Submit a manuscript" href="https://www.nihms.nih.gov/" ref="reftype=publisher&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="rect" coords="0,0,499,74" alt="HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;" title="HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;" href="https://www.ncbi.nlm.nih.gov/pmc/about/public-access/" ref="reftype=publisher&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"></map></div> </div>
        
        <!--component id='MainPortlet' label='search-reference'/-->
        
        <!-- Book content -->
        <div class="">
            
        
            
            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'" id="ui-ncbiinpagenav-1"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><span role="menubar"><a href="#" role="menuitem" aria-expanded="false" aria-haspopup="true">Gastroenterology</a></span>. Author manuscript; available in PMC 2018 Apr 1.</div><div></div><div>Published in final edited form as:</div><div style="margin-left:1em"><div class="fm-vol-iss-date"><a href="/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=28043905" target="pmc_ext" ref="reftype=publisher&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access"><span class="cit">Gastroenterology. 2017 Apr; 152(5): 1078–1089. </span></a></div><span class="fm-vol-iss-date">Published online 2016 Dec 30. </span> <span class="doi">doi:&nbsp;<a href="//dx.doi.org/10.1053%2Fj.gastro.2016.12.016" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1053/j.gastro.2016.12.016</a></span></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC5367948</span></div><div class="fm-citation-manuscriptid"><span class="fm-citation-ids-label">NIHMSID: </span><span>NIHMS840066</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/28043905">28043905</a></div></div></div></div><h1 class="content-title">Association of Liver Injury From Specific Drugs, or Groups of Drugs,
With Polymorphisms in HLA and Other Genes in a Genome-wide Association
Study</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Nicoletti%20P%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620995512480" co-class="co-affbox">Paola Nicoletti</a>,<sup>1,</sup><sup>*</sup> <a href="/pubmed/?term=Aithal%20GP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620999378240" co-class="co-affbox">Guruprasad P. Aithal</a>,<sup>2,</sup><sup>*</sup> <a href="/pubmed/?term=Bjornsson%20ES%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620995510368" co-class="co-affbox">Einar S. Bjornsson</a>,<sup>3</sup> <a href="/pubmed/?term=Andrade%20RJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139621027862512" co-class="co-affbox">Raul J. Andrade</a>,<sup>4</sup> <a href="/pubmed/?term=Sawle%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139621028349024" co-class="co-affbox">Ashley Sawle</a>,<sup>1</sup> <a href="/pubmed/?term=Arrese%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139621028347040" co-class="co-affbox">Marco Arrese</a>,<sup>5</sup> <a href="/pubmed/?term=Barnhart%20HX%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620962755904" co-class="co-affbox">Huiman X. Barnhart</a>,<sup>6</sup> <a href="/pubmed/?term=Bondon-Guitton%20E%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620998203184" co-class="co-affbox">Emmanuelle Bondon-Guitton</a>,<sup>7</sup> <a href="/pubmed/?term=Hayashi%20PH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620998201200" co-class="co-affbox">Paul H. Hayashi</a>,<sup>8</sup> <a href="/pubmed/?term=Bessone%20F%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620984591440" co-class="co-affbox">Fernando Bessone</a>,<sup>9</sup> <a href="/pubmed/?term=Carvajal%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620997237664" co-class="co-affbox">Alfonso Carvajal</a>,<sup>10</sup> <a href="/pubmed/?term=Cascorbi%20I%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620997235680" co-class="co-affbox">Ingolf Cascorbi</a>,<sup>11</sup> <a href="/pubmed/?term=Cirulli%20ET%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139621035049152" co-class="co-affbox">Elizabeth T. Cirulli</a>,<sup>6</sup> <a href="/pubmed/?term=Chalasani%20N%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139621072279376" co-class="co-affbox">Naga Chalasani</a>,<sup>12</sup> <a href="/pubmed/?term=Conforti%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139621072277392" co-class="co-affbox">Anita Conforti</a>,<sup>13</sup> <a href="/pubmed/?term=Coulthard%20SA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620985089104" co-class="co-affbox">Sally A. Coulthard</a>,<sup>14</sup> <a href="/pubmed/?term=Daly%20MJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620996134608" co-class="co-affbox">Mark J. Daly</a>,<sup>15</sup> <a href="/pubmed/?term=Day%20CP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620996132624" co-class="co-affbox">Christopher P. Day</a>,<sup>14</sup> <a href="/pubmed/?term=Dillon%20JF%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620985177136" co-class="co-affbox">John F. Dillon</a>,<sup>16</sup> <a href="/pubmed/?term=Fontana%20RJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620994064848" co-class="co-affbox">Robert J. Fontana</a>,<sup>17</sup> <a href="/pubmed/?term=Grove%20JI%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620994062976" co-class="co-affbox">Jane I. Grove</a>,<sup>2</sup> <a href="/pubmed/?term=Hallberg%20P%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620984588608" co-class="co-affbox">Pär Hallberg</a>,<sup>18</sup> <a href="/pubmed/?term=Hern%26%23x000e1%3Bndez%20N%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620967147920" co-class="co-affbox">Nelia Hernández</a>,<sup>19</sup> <a href="/pubmed/?term=Ib%26%23x000e1%3B%26%23x000f1%3Bez%20L%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620967146048" co-class="co-affbox">Luisa Ibáñez</a>,<sup>20</sup> <a href="/pubmed/?term=Kullak-Ublick%20GA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139621029270976" co-class="co-affbox">Gerd A. Kullak-Ublick</a>,<sup>21</sup> <a href="/pubmed/?term=Laitinen%20T%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139621029268992" co-class="co-affbox">Tarja Laitinen</a>,<sup>22</sup> <a href="/pubmed/?term=Larrey%20D%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620996452464" co-class="co-affbox">Dominique Larrey</a>,<sup>23</sup> <a href="/pubmed/?term=Lucena%20MI%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139621070501104" co-class="co-affbox">M. Isabel Lucena</a>,<sup>4</sup> <a href="/pubmed/?term=Maitland-van%20der%20Zee%20AH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139621070499120" co-class="co-affbox">Anke H. Maitland-van der Zee</a>,<sup>24</sup> <a href="/pubmed/?term=Martin%20JH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620996062880" co-class="co-affbox">Jennifer H. Martin</a>,<sup>25</sup> <a href="/pubmed/?term=Molokhia%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620995959648" co-class="co-affbox">Mariam Molokhia</a>,<sup>26</sup> <a href="/pubmed/?term=Pirmohamed%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620995957664" co-class="co-affbox">Munir Pirmohamed</a>,<sup>27</sup> <a href="/pubmed/?term=Powell%20EE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620967113472" co-class="co-affbox">Elizabeth E. Powell</a>,<sup>28</sup> <a href="/pubmed/?term=Qin%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139621034520944" co-class="co-affbox">Shengying Qin</a>,<sup>29</sup> <a href="/pubmed/?term=Serrano%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139621034518960" co-class="co-affbox">Jose Serrano</a>,<sup>30</sup> <a href="/pubmed/?term=Stephens%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139621070458832" co-class="co-affbox">Camilla Stephens</a>,<sup>4</sup> <a href="/pubmed/?term=Stolz%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139621070456848" co-class="co-affbox">Andrew Stolz</a>,<sup>31</sup> <a href="/pubmed/?term=Wadelius%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139621033258448" co-class="co-affbox">Mia Wadelius</a>,<sup>18</sup> <a href="/pubmed/?term=Watkins%20PB%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620998045760" co-class="co-affbox">Paul B. Watkins</a>,<sup>32</sup> <a href="/pubmed/?term=Floratos%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620998043776" co-class="co-affbox">Aris Floratos</a>,<sup>1</sup> <a href="/pubmed/?term=Shen%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620997575360" co-class="co-affbox">Yufeng Shen</a>,<sup>1</sup> <a href="/pubmed/?term=Nelson%20MR%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620962753792" co-class="co-affbox">Matthew R. Nelson</a>,<sup>33</sup> <a href="/pubmed/?term=Urban%20TJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620962751808" co-class="co-affbox">Thomas J. Urban</a>,<sup>34,</sup><sup>#</sup> and  <a href="/pubmed/?term=Daly%20AK%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905" class="affpopup" co-rid="_co_idm139620998193392" co-class="co-affbox">Ann K. Daly</a><sup>14,</sup><sup>#</sup>, on behalf of International DILI consortium (iDILIC), Drug-induced
liver injury network (DILIN) investigators and International Serious Adverse
Events Consortium (iSAEC)</div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm139620995512480"><h3 class="no_margin">Paola Nicoletti</h3><p><sup>1</sup>Department of Systems Biology, Columbia University, New York </p><div>Find articles by <a href="/pubmed/?term=Nicoletti%20P%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Paola Nicoletti</a></div></div><div id="_co_idm139620999378240"><h3 class="no_margin">Guruprasad P. Aithal</h3><p><sup>2</sup>National Institute for Health Research (NIHR) Nottingham Digestive Diseases Biomedical Research Unit, Nottingham University Hospital NHS Trust and University of Nottingham, Nottingham, UK </p><div>Find articles by <a href="/pubmed/?term=Aithal%20GP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Guruprasad P. Aithal</a></div></div><div id="_co_idm139620995510368"><h3 class="no_margin">Einar S. Bjornsson</h3><p><sup>3</sup>Department of Internal Medicine, Landspitali University Hospital, Reykjavik, Iceland </p><div>Find articles by <a href="/pubmed/?term=Bjornsson%20ES%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Einar S. Bjornsson</a></div></div><div id="_co_idm139621027862512"><h3 class="no_margin">Raul J. Andrade</h3><p><sup>4</sup>UGC Digestivo, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) </p><div>Find articles by <a href="/pubmed/?term=Andrade%20RJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Raul J. Andrade</a></div></div><div id="_co_idm139621028349024"><h3 class="no_margin">Ashley Sawle</h3><p><sup>1</sup>Department of Systems Biology, Columbia University, New York </p><div>Find articles by <a href="/pubmed/?term=Sawle%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Ashley Sawle</a></div></div><div id="_co_idm139621028347040"><h3 class="no_margin">Marco Arrese</h3><p><sup>5</sup>Departmento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile </p><div>Find articles by <a href="/pubmed/?term=Arrese%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Marco Arrese</a></div></div><div id="_co_idm139620962755904"><h3 class="no_margin">Huiman X. Barnhart</h3><p><sup>6</sup>Duke University, Durham, North Carolina </p><div>Find articles by <a href="/pubmed/?term=Barnhart%20HX%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Huiman X. Barnhart</a></div></div><div id="_co_idm139620998203184"><h3 class="no_margin">Emmanuelle Bondon-Guitton</h3><p><sup>7</sup>Universite de Toulouse, Toulouse, France </p><div>Find articles by <a href="/pubmed/?term=Bondon-Guitton%20E%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Emmanuelle Bondon-Guitton</a></div></div><div id="_co_idm139620998201200"><h3 class="no_margin">Paul H. Hayashi</h3><p><sup>8</sup>Department of Internal Medicine, University of North Carolina – Chapel Hill, North Carolina </p><div>Find articles by <a href="/pubmed/?term=Hayashi%20PH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Paul H. Hayashi</a></div></div><div id="_co_idm139620984591440"><h3 class="no_margin">Fernando Bessone</h3><p><sup>9</sup>Servicio de Gastroenterología y Hepatología, Universidad Nacional de Rosario, Rosario, Argentina </p><div>Find articles by <a href="/pubmed/?term=Bessone%20F%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Fernando Bessone</a></div></div><div id="_co_idm139620997237664"><h3 class="no_margin">Alfonso Carvajal</h3><p><sup>10</sup>Universidad de Valladolid, Valladolid, Spain </p><div>Find articles by <a href="/pubmed/?term=Carvajal%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Alfonso Carvajal</a></div></div><div id="_co_idm139620997235680"><h3 class="no_margin">Ingolf Cascorbi</h3><p><sup>11</sup>Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Kiel, Germany </p><div>Find articles by <a href="/pubmed/?term=Cascorbi%20I%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Ingolf Cascorbi</a></div></div><div id="_co_idm139621035049152"><h3 class="no_margin">Elizabeth T. Cirulli</h3><p><sup>6</sup>Duke University, Durham, North Carolina </p><div>Find articles by <a href="/pubmed/?term=Cirulli%20ET%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Elizabeth T. Cirulli</a></div></div><div id="_co_idm139621072279376"><h3 class="no_margin">Naga Chalasani</h3><p><sup>12</sup>Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana </p><div>Find articles by <a href="/pubmed/?term=Chalasani%20N%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Naga Chalasani</a></div></div><div id="_co_idm139621072277392"><h3 class="no_margin">Anita Conforti</h3><p><sup>13</sup>University Hospital, Verona, Italy </p><div>Find articles by <a href="/pubmed/?term=Conforti%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Anita Conforti</a></div></div><div id="_co_idm139620985089104"><h3 class="no_margin">Sally A. Coulthard</h3><p><sup>14</sup>Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK </p><div>Find articles by <a href="/pubmed/?term=Coulthard%20SA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Sally A. Coulthard</a></div></div><div id="_co_idm139620996134608"><h3 class="no_margin">Mark J. Daly</h3><p><sup>15</sup>Broad Institute of Harvard and MIT, Boston </p><div>Find articles by <a href="/pubmed/?term=Daly%20MJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Mark J. Daly</a></div></div><div id="_co_idm139620996132624"><h3 class="no_margin">Christopher P. Day</h3><p><sup>14</sup>Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK </p><div>Find articles by <a href="/pubmed/?term=Day%20CP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Christopher P. Day</a></div></div><div id="_co_idm139620985177136"><h3 class="no_margin">John F. Dillon</h3><p><sup>16</sup>Medical Research Institute, University of Dundee,Ninewells Hospital, Dundee, UK </p><div>Find articles by <a href="/pubmed/?term=Dillon%20JF%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">John F. Dillon</a></div></div><div id="_co_idm139620994064848"><h3 class="no_margin">Robert J. Fontana</h3><p><sup>17</sup>University of Michigan, Ann Arbor, Michigan </p><div>Find articles by <a href="/pubmed/?term=Fontana%20RJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Robert J. Fontana</a></div></div><div id="_co_idm139620994062976"><h3 class="no_margin">Jane I. Grove</h3><p><sup>2</sup>National Institute for Health Research (NIHR) Nottingham Digestive Diseases Biomedical Research Unit, Nottingham University Hospital NHS Trust and University of Nottingham, Nottingham, UK </p><div>Find articles by <a href="/pubmed/?term=Grove%20JI%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Jane I. Grove</a></div></div><div id="_co_idm139620984588608"><h3 class="no_margin">Pär Hallberg</h3><p><sup>18</sup>Department of Medical Sciences and Science for Life Laboratory, Uppsala University, Uppsala, Sweden </p><div>Find articles by <a href="/pubmed/?term=Hallberg%20P%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Pär Hallberg</a></div></div><div id="_co_idm139620967147920"><h3 class="no_margin">Nelia Hernández</h3><p><sup>19</sup>Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay </p><div>Find articles by <a href="/pubmed/?term=Hern%26%23x000e1%3Bndez%20N%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Nelia Hernández</a></div></div><div id="_co_idm139620967146048"><h3 class="no_margin">Luisa Ibáñez</h3><p><sup>20</sup>Fundació Institut Català de Farmacologia, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain </p><div>Find articles by <a href="/pubmed/?term=Ib%26%23x000e1%3B%26%23x000f1%3Bez%20L%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Luisa Ibáñez</a></div></div><div id="_co_idm139621029270976"><h3 class="no_margin">Gerd A. Kullak-Ublick</h3><p><sup>21</sup>Department of Clinical Pharmacology and Toxicology, University Hospital and University of Zurich, Zurich, Switzerland </p><div>Find articles by <a href="/pubmed/?term=Kullak-Ublick%20GA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Gerd A. Kullak-Ublick</a></div></div><div id="_co_idm139621029268992"><h3 class="no_margin">Tarja Laitinen</h3><p><sup>22</sup>Clinical Research Unit for Pulmonary Diseases, Helsinki University Central Hospital, Helsinki, Finland </p><div>Find articles by <a href="/pubmed/?term=Laitinen%20T%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Tarja Laitinen</a></div></div><div id="_co_idm139620996452464"><h3 class="no_margin">Dominique Larrey</h3><p><sup>23</sup>Liver Unit, CHU St Eloi Hospital, Montpellier, France </p><div>Find articles by <a href="/pubmed/?term=Larrey%20D%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Dominique Larrey</a></div></div><div id="_co_idm139621070501104"><h3 class="no_margin">M. Isabel Lucena</h3><p><sup>4</sup>UGC Digestivo, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) </p><div>Find articles by <a href="/pubmed/?term=Lucena%20MI%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">M. Isabel Lucena</a></div></div><div id="_co_idm139621070499120"><h3 class="no_margin">Anke H. Maitland-van der Zee</h3><p><sup>24</sup>Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, Netherlands </p><div>Find articles by <a href="/pubmed/?term=Maitland-van%20der%20Zee%20AH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Anke H. Maitland-van der Zee</a></div></div><div id="_co_idm139620996062880"><h3 class="no_margin">Jennifer H. Martin</h3><p><sup>25</sup>School of Medicine and Public Health, University of Newcastle, New South Wales, Australia </p><div>Find articles by <a href="/pubmed/?term=Martin%20JH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Jennifer H. Martin</a></div></div><div id="_co_idm139620995959648"><h3 class="no_margin">Mariam Molokhia</h3><p><sup>26</sup>Department of Primary Care and Public Health Sciences, King's College, London, UK </p><div>Find articles by <a href="/pubmed/?term=Molokhia%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Mariam Molokhia</a></div></div><div id="_co_idm139620995957664"><h3 class="no_margin">Munir Pirmohamed</h3><p><sup>27</sup>Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK </p><div>Find articles by <a href="/pubmed/?term=Pirmohamed%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Munir Pirmohamed</a></div></div><div id="_co_idm139620967113472"><h3 class="no_margin">Elizabeth E. Powell</h3><p><sup>28</sup>Centre for Liver Disease Research, School of Medicine, The University of Queensland, Brisbane, QLD, Australia </p><div>Find articles by <a href="/pubmed/?term=Powell%20EE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Elizabeth E. Powell</a></div></div><div id="_co_idm139621034520944"><h3 class="no_margin">Shengying Qin</h3><p><sup>29</sup>Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Shanghai Jiao Tong University, Shanghai, China </p><div>Find articles by <a href="/pubmed/?term=Qin%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Shengying Qin</a></div></div><div id="_co_idm139621034518960"><h3 class="no_margin">Jose Serrano</h3><p><sup>30</sup>National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland </p><div>Find articles by <a href="/pubmed/?term=Serrano%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Jose Serrano</a></div></div><div id="_co_idm139621070458832"><h3 class="no_margin">Camilla Stephens</h3><p><sup>4</sup>UGC Digestivo, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) </p><div>Find articles by <a href="/pubmed/?term=Stephens%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Camilla Stephens</a></div></div><div id="_co_idm139621070456848"><h3 class="no_margin">Andrew Stolz</h3><p><sup>31</sup>University of Southern California, Los Angeles, California </p><div>Find articles by <a href="/pubmed/?term=Stolz%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Andrew Stolz</a></div></div><div id="_co_idm139621033258448"><h3 class="no_margin">Mia Wadelius</h3><p><sup>18</sup>Department of Medical Sciences and Science for Life Laboratory, Uppsala University, Uppsala, Sweden </p><div>Find articles by <a href="/pubmed/?term=Wadelius%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Mia Wadelius</a></div></div><div id="_co_idm139620998045760"><h3 class="no_margin">Paul B. Watkins</h3><p><sup>32</sup>University of North Carolina Institute for Drug Safety Sciences, Eshelman School of Pharmacy, North Carolina </p><div>Find articles by <a href="/pubmed/?term=Watkins%20PB%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Paul B. Watkins</a></div></div><div id="_co_idm139620998043776"><h3 class="no_margin">Aris Floratos</h3><p><sup>1</sup>Department of Systems Biology, Columbia University, New York </p><div>Find articles by <a href="/pubmed/?term=Floratos%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Aris Floratos</a></div></div><div id="_co_idm139620997575360"><h3 class="no_margin">Yufeng Shen</h3><p><sup>1</sup>Department of Systems Biology, Columbia University, New York </p><div>Find articles by <a href="/pubmed/?term=Shen%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Yufeng Shen</a></div></div><div id="_co_idm139620962753792"><h3 class="no_margin">Matthew R. Nelson</h3><p><sup>33</sup>Target Sciences, GSK, King of Prussia, Pennsylvania </p><div>Find articles by <a href="/pubmed/?term=Nelson%20MR%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Matthew R. Nelson</a></div></div><div id="_co_idm139620962751808"><h3 class="no_margin">Thomas J. Urban</h3><p><sup>34</sup>UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina </p><div>Find articles by <a href="/pubmed/?term=Urban%20TJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Thomas J. Urban</a></div></div><div id="_co_idm139620998193392"><h3 class="no_margin">Ann K. Daly</h3><p><sup>14</sup>Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK </p><div>Find articles by <a href="/pubmed/?term=Daly%20AK%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28043905">Ann K. Daly</a></div></div></div></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm139620997047216_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm139620997047216_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm139620997047216_ai" style="display:none"><div class="fm-affl" id="A1" lang="en"><sup>1</sup>Department of Systems Biology, Columbia University, New York </div><div class="fm-affl" id="A2" lang="en"><sup>2</sup>National Institute for Health Research (NIHR) Nottingham Digestive Diseases Biomedical Research Unit, Nottingham University Hospital NHS Trust and University of Nottingham, Nottingham, UK </div><div class="fm-affl" id="A3" lang="en"><sup>3</sup>Department of Internal Medicine, Landspitali University Hospital, Reykjavik, Iceland </div><div class="fm-affl" id="A4" lang="en"><sup>4</sup>UGC Digestivo, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) </div><div class="fm-affl" id="A5" lang="en"><sup>5</sup>Departmento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile </div><div class="fm-affl" id="A6" lang="en"><sup>6</sup>Duke University, Durham, North Carolina </div><div class="fm-affl" id="A7" lang="en"><sup>7</sup>Universite de Toulouse, Toulouse, France </div><div class="fm-affl" id="A8" lang="en"><sup>8</sup>Department of Internal Medicine, University of North Carolina – Chapel Hill, North Carolina </div><div class="fm-affl" id="A9" lang="en"><sup>9</sup>Servicio de Gastroenterología y Hepatología, Universidad Nacional de Rosario, Rosario, Argentina </div><div class="fm-affl" id="A10" lang="en"><sup>10</sup>Universidad de Valladolid, Valladolid, Spain </div><div class="fm-affl" id="A11" lang="en"><sup>11</sup>Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Kiel, Germany </div><div class="fm-affl" id="A12" lang="en"><sup>12</sup>Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana </div><div class="fm-affl" id="A13" lang="en"><sup>13</sup>University Hospital, Verona, Italy </div><div class="fm-affl" id="A14" lang="en"><sup>14</sup>Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK </div><div class="fm-affl" id="A15" lang="en"><sup>15</sup>Broad Institute of Harvard and MIT, Boston </div><div class="fm-affl" id="A16" lang="en"><sup>16</sup>Medical Research Institute, University of Dundee,Ninewells Hospital, Dundee, UK </div><div class="fm-affl" id="A17" lang="en"><sup>17</sup>University of Michigan, Ann Arbor, Michigan </div><div class="fm-affl" id="A18" lang="en"><sup>18</sup>Department of Medical Sciences and Science for Life Laboratory, Uppsala University, Uppsala, Sweden </div><div class="fm-affl" id="A19" lang="en"><sup>19</sup>Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay </div><div class="fm-affl" id="A20" lang="en"><sup>20</sup>Fundació Institut Català de Farmacologia, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain </div><div class="fm-affl" id="A21" lang="en"><sup>21</sup>Department of Clinical Pharmacology and Toxicology, University Hospital and University of Zurich, Zurich, Switzerland </div><div class="fm-affl" id="A22" lang="en"><sup>22</sup>Clinical Research Unit for Pulmonary Diseases, Helsinki University Central Hospital, Helsinki, Finland </div><div class="fm-affl" id="A23" lang="en"><sup>23</sup>Liver Unit, CHU St Eloi Hospital, Montpellier, France </div><div class="fm-affl" id="A24" lang="en"><sup>24</sup>Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, Netherlands </div><div class="fm-affl" id="A25" lang="en"><sup>25</sup>School of Medicine and Public Health, University of Newcastle, New South Wales, Australia </div><div class="fm-affl" id="A26" lang="en"><sup>26</sup>Department of Primary Care and Public Health Sciences, King's College, London, UK </div><div class="fm-affl" id="A27" lang="en"><sup>27</sup>Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK </div><div class="fm-affl" id="A28" lang="en"><sup>28</sup>Centre for Liver Disease Research, School of Medicine, The University of Queensland, Brisbane, QLD, Australia </div><div class="fm-affl" id="A29" lang="en"><sup>29</sup>Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Shanghai Jiao Tong University, Shanghai, China </div><div class="fm-affl" id="A30" lang="en"><sup>30</sup>National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland </div><div class="fm-affl" id="A31" lang="en"><sup>31</sup>University of Southern California, Los Angeles, California </div><div class="fm-affl" id="A32" lang="en"><sup>32</sup>University of North Carolina Institute for Drug Safety Sciences, Eshelman School of Pharmacy, North Carolina </div><div class="fm-affl" id="A33" lang="en"><sup>33</sup>Target Sciences, GSK, King of Prussia, Pennsylvania </div><div class="fm-affl" id="A34" lang="en"><sup>34</sup>UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina </div><div id="CR1"><strong>Correspondence to:</strong> Ann K. Daly, <a href="mailto:dev@null" data-email="ku.ca.lcn@ylad.k.a" class="oemail">ku.ca.lcn@ylad.k.a</a>, Tel +44 191 208 7031, Institute of Cellular Medicine, Newcastle University, Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, UK</div><div id="FN1"><sup>*</sup>Authors share co-first authorship</div><div id="FN2"><sup>#</sup>Authors share co-senior authorship</div></div><div class="fm-article-notes fm-panel half_rhythm"></div><div class="permissions fm-panel half_rhythm hide" id="idm139620997047216_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright notice</a> </div><div><a href="#FN5">Publisher's Disclaimer</a></div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>The publisher's final edited version of this article is available  at <a href="/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=28043905" target="pmc_ext" ref="reftype=publisher&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access">Gastroenterology</a></div><div>See other articles in PMC that <a href="/pmc/articles/PMC5367948/citedby/">cite</a> the published article.</div></div></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><div class="goto jig-ncbiinpagenav-goto-container"><span role="menubar"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="menuitem" aria-expanded="false" aria-haspopup="true">Go to:</a></span></div><h2 class="ui-helper-clearfix" id="ui-ncbiinpagenav-heading-3">Associated Data</h2><dl data-count="1" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>01: </strong><strong>Figure S1.</strong> Scatterplots representing the first two
principal components of the current study cohort. The homogenous
distribution between cases and controls across the three major European
clusters is shown. In panel (a) cases from phase II are highlighted in red
and the cases from phase I in orange. In panel (b) the cholestatic/mixed
cases are highlighted in red and the hepatocellular cases in blue.<p><strong>Figure S2.</strong> Regional Manhattan plots for chromosome 2
and 4 in the region of the rs72631567 and rs28521457 signals. (A) Chromosome
2 for the overall cohort, (B) Chromosome 2 for the overall cohort
conditioned on rs72631567. (C) Chromosome 4 for the HC only cohort, (D)
Chromosome 4 for the HC only cohort conditioned on rs28521457.</p><p><strong>Figure S3</strong>. QQ plots. (a) for the overall original
analysis (b) after eliminating variants in MHC region. The QQ plot in the
(b) panel highlights the signal on chromosome 2. The inflation factor is
1.05 after correction and 4.65 before correction.</p><p><strong>Figure S4</strong>. Scatterplot representing the first two
principal components of the current study cohort. The A*33:01-positive cases
and their injury type are highlighted. A*33:01-positive cases are
homogenously distributed in all the major population clusters.</p><p><strong>Figure S5.</strong> MHC Regional Manhattan plots for (a) the
overall cohort (b) the same cohort conditioned on A*33:01 (purple dot) and
(c) the same cohort conditioned on rs114577328 (purple dot).</p><p><strong>Figure S6</strong>. QQ plot for (a) Terbinafine cases only, (b)
Cholestatic/Mixed cases only, (c) Hepatocellular cases only.</p><p><strong>Figure S7.</strong> MHC Region Manhattan plots for (a) all
cholestatic/mixed cases (b) the same cases conditioned on rs114577328
(purple dot), the top SNP (c) the same cases conditioned on A*33:01 (purple
dot), the top HLA allele</p><p><strong>Figure S8.</strong> Manhattan plots for DILI due to (A) Anti-TB
drugs, (B) Fluoroquinolones, (C) NSAIDs, (D) Diclofenac (E)
Nitrofurantoin.</p><p><strong>Figure S9.</strong> Regional Manhattan plots for chromosome 18
in the area of the rs116561224 signal for (a) statin-induced DILI cases and
(b) the same cases with conditioning on rs116561224</p><p><strong>Table S1</strong>. Causal drugs in the replication cohort.</p><p><strong>Table S2</strong>. Genotyping details for the DILI control
cohorts</p><p><strong>Table S3.</strong> Causative drugs across the overall DILI
cohort</p><p><strong>Table S4</strong>. Effect of the A*33:01, rs72631567 and
rs28521457 signals across populations and recruitment phases</p><p><strong>Table S5.</strong> Missing genotypes rate for the most
associated SNPs within case and control groups in the comparisons where SNPs
were significant</p><p><strong>Table S6</strong>. Causative drugs across the rs72631567 signal
on chromosome 2</p><p><strong>Table S7.</strong> Summary of A*33:01-B*14:02-C*08:02 haplotype
specific analysis across study cohorts</p><p><strong>Table S8.</strong> Summary of the validation by direct HLA
typing</p><p><strong>Table S9.</strong> The A*33:01 signal across the main six
A*33:01-associated drugs by type of injury</p><p><strong>Table S10.</strong> List of all causal drugs where at least one
case carries a A*33:01 allele</p><p><strong>Table S11</strong>. The most represented causative drugs across
the rs28521457 signal on chromosome 4</p><p><strong>Table S12.</strong> Summary of drug and class comparisons with
more than 40 samples</p><p><strong>Table S13.</strong> The most associated variants for each drug
in the class-specific analysis</p><p><strong>Table S14.</strong> Causative drugs associated with rs116561224
signal in the statin cohort</p><p><strong>Table S15.</strong> Causative drugs associated with the
rs114577328/A*33:01 signal in the additional case set</p><p><strong>Table S16.</strong> Causative drugs associated with the
chromosome 2 rs72631567 signal in the additional case set</p><p><strong>Table S17.</strong> Causative drugs associated with the
chromosome 4 rs28521457 signal in the additional case set</p></div><div><a href="/pmc/articles/PMC5367948/bin/NIHMS840066-supplement-01.pdf" data-ga-action="click_feat_suppl">NIHMS840066-supplement-01.pdf</a><span style="color:gray"> (2.2M)</span></div><div class="small guid">GUID:&nbsp;FEBBA883-349C-4C52-965A-A451B5823021</div></div></dd></dl></div><div id="idm139620996736016" class="tsec sec" lang="en"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm139620996736016title">Abstract</h2><!--article-meta--><div><div id="S1" class="sec sec-first"><h3 id="S1title">BACKGROUND &amp; AIMS</h3><p id="P3" class="p p-first-last">We performed a genome-wide association study (GWAS) to identify
genetic risk factors for drug-induced liver injury (DILI) from licensed
drugs without previously reported genetic risk factors.</p></div><div id="S2" class="sec"><h3 id="S2title">METHODS</h3><p id="P4" class="p p-first-last">We performed a GWAS of 862 persons with DILI and 10588
population-matched controls. The first set of cases was recruited prior to
May 2009 in Europe (n=137) or the USA (n=274). The second set of cases were
identified from May 2009 through May 2013 from international collaborative
studies performed in Europe, the USA and South America. For the GWAS, we
included only cases of European ancestry associated with a particular drug
(but not flucloxacillin or amoxicillin-clavulanate). We used DNA samples
from all subjects to analyze human leukocyte antigen (HLA) genes and single
nucleotide polymorphisms (SNPs). After the discovery analysis was concluded,
we validated our findings using data from 283 European patients with
diagnosis of DILI associated with various drugs.</p></div><div id="S3" class="sec"><h3 id="S3title">RESULTS</h3><p id="P5" class="p p-first-last">We associated DILI with rs114577328 (a proxy for A*33:01 a HLA class
I allele; odds ratio [OR], 2.7; 95% CI, 1.9–3.8;
<em>P</em>=2.4×10−8) and with rs72631567 on chromosome
2 (OR, 2.0; 95% CI, 1.6–2.5;
<em>P</em>=9.7×10−9). The association with A*33:01 was
mediated by large effects for terbinafine-, fenofibrate-, and
ticlopidine-related DILI. The variant on chromosome 2 was associated with
DILI from a variety of drugs. Further phenotypic analysis indicated that the
association between DILI and A*33:01 was significant, genome wide, for
cholestatic and mixed DILI, but not for hepatocellular DILI; the
polymorphism on chromosome 2 associated with cholestatic and mixed DILI as
well as hepatocellular DILI. We identified an association between rs28521457
(within the <em>LRBA</em> gene) and only hepatocellular DILI (OR,
2.1; 95% CI, 1.6–2.7; <em>P</em>=4.8×10−9). We
did not associate any specific drug classes with genetic polymorphisms,
except for statin-associated DILI, which was associated with rs116561224 on
chromosome 18 (OR=5.4; 95% CI, 3.0–9.5;
<em>P</em>=7.1×10−9). We validated the association
between A*33:01 terbinafine- and sertraline-induced DILI. We could not
validate the association between DILI and rs72631567, rs28521457, or
rs116561224.</p></div><div id="S4" class="sec sec-last"><h3 id="S4title">CONCLUSIONS</h3><p id="P6" class="p p-first-last">In a GWAS of persons of European descent with DILI, we associated
HLA-A*33:01 with DILI due to terbinafine and possibly fenofibrate and
ticlopidine. We identified polymorphisms that appear to be associated with
DILI from statins, as well as 2 non–drug-specific risk factors.</p></div></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">medication, liver damage, side effect, anti-fungal agent</span></div></div><div id="S5" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S5title">Introduction</h2><p id="P7" class="p p-first">Hepatotoxicity is the second most common cause of drug attrition during
development as well as for post-marketing withdrawal,<sup><a href="#R1" rid="R1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445506">1</a></sup> and idiosyncratic drug-induced liver injury (DILI)
accounts for 11%-17% of cases of acute liver failure in the United States and
Europe.<sup><a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445500">2</a>, <a href="#R3" rid="R3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445514">3</a></sup> The typical incidence of DILI varies from
approximately 1% with the anti-tumor necrosis factor agents<sup><a href="#R4" rid="R4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445524">4</a></sup> to 0.04% with some widely used
antimicrobials such as amoxicillin-clavulanate.<sup><a href="#R5" rid="R5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445509">5</a></sup> During the past 15 years, increasing progress on identifying
genetic risk factors for DILI has been made. In particular, associations with HLA
class I and II alleles have been reported for DILI caused by a range of drugs,
though a particular HLA genotype does not appear to be relevant to all forms of
idiosyncratic DILI.<sup><a href="#R6" rid="R6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445523">6</a></sup></p><p id="P8">Previously, GWAS involving cohorts of DILI cases related to one particular
drug only have resulted in identification of one or more drug-specific HLA risk
alleles.<sup><a href="#R7" rid="R7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445491">7</a>-<a href="#R11" rid="R11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445497">11</a></sup> A large study involving 783 DILI cases due to a
range of different drugs also resulted in a genome-wide significant HLA signal, but
this association was abolished once 296 cases of DILI due to flucloxacillin and
amoxicillin-clavulanate were excluded.<sup><a href="#R12" rid="R12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445485">12</a></sup> This partly reflects the fact that amoxicillin-clavulanate is a
very common cause of DILI worldwide and flucloxacillin is an equally common cause in
a number of Northern European countries.<sup><a href="#R13" rid="R13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445547">13</a></sup> Therefore, DNA collections from DILI cases generally will
be highly enriched in cases relating to these two drugs, making detection of
associations related to other compounds more difficult.</p><p id="P9" class="p p-last">We have expanded our previous study of DILI caused by a range of different
drugs,<sup><a href="#R12" rid="R12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445533">12</a></sup> and after
excluding cases relating to amoxicillin-clavulanate and flucloxacillin, we have more
than doubled the number of cases with additions from Europe, Australia, South
America and the United States. We now report that HLA-A*33:01 is associated with
risk of DILI, particularly due to terbinafine, fenofibrate and ticlopidine and
especially with a cholestatic or mixed phenotype. We have also found novel non-major
histocompatibility complex (MHC) related signals apparently shared across a range of
different drugs; an intronic SNP, in the LPS-responsive vesicle trafficking, beach
and anchor containing (LRBA) gene is associated with hepatocellular DILI and an
intergenic SNP on chromosome 2, rs72631567, with DILI generally. An additional
drug-specific genome-wide significant signal which could not be confirmed is also
reported.</p></div><div id="S6" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S6title">Materials and Methods</h2><div id="S7" class="sec sec-first"><h3 id="S7title">DILI discovery cohort</h3><p id="P10" class="p p-first">The cases in the study were from two separate recruitment phases. Phase
I consists of 411 cases included in a previous study (from DILIN, DILIGEN and
Eudragene)<sup><a href="#R12" rid="R12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445510">12</a></sup> and phase
II more recently recruited cases (n=451) of which a small subset was included in
a recent report.<sup><a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445501">14</a></sup></p><div id="S8" class="sec"><p></p><h4 id="S8title" class="inline">Phase I cases </h4><p id="P11" class="p p-first-last">These cases included 413 DILI cases not due to
amoxicillin-clavulanate or flucloxacillin, with a defined casual drug and
with causality score greater than possible (RUCAM score≥3) recruited
in Europe (n=137) or the USA (n=274) prior to 2009. Clinical characteristics
of these cases and methods used for genotyping have been described in detail
previously.<sup><a href="#R12" rid="R12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445481">12</a></sup>
Additional exome chip analysis (Illumina Infinium HumanCoreExome BeadChip)
was performed on 150 of these 413 cases at the Broad Institute, Boston.</p></div><div id="S9" class="sec"><p></p><h4 id="S9title" class="inline">Phase II case recruitment-iDILIC </h4><p id="P12" class="p p-first-last">The iDILIC cases were recruited between May 2009 and May 2013 as
part of an international collaborative study involving recruitment centers
in the United Kingdom (Newcastle, Nottingham, Liverpool, London, Dundee),
Sweden (Uppsala and Gothenburg), Spain (Malaga and Barcelona), France
(Montpellier), the Netherlands (Utrecht), Germany (Kiel), Australia
(Brisbane), Switzerland (Zurich), Finland (Helsinki), Argentina (Rosario),
Uruguay (Montevideo) and Chile (Santiago). All participants provided written
informed consent and each study had been approved by the appropriate
national or institutional ethical review boards. For the GWAS, only cases of
European ancestry where there were at least 2 cases due to a particular drug
available (when phase I cases from Europe and the USA were also considered)
and where the DILI was not due to either flucloxacillin or
amoxicillin-clavulanate were included (n=339). Clinical inclusion criteria
for all cases were those described by Aithal et al.<sup><a href="#R15" rid="R15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445492">15</a></sup></p></div><div id="S10" class="sec sec-last"><p></p><h4 id="S10title" class="inline">Phase II case recruitment-DILIN </h4><p id="P13" class="p p-first-last">Details of the USA-based DILIN prospective study including IRB
approval information have been described previously.<sup><a href="#R16" rid="R16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445526">16</a></sup> A total of 112 eligible
new cases of European ancestry and ≥ 18 years were included in the
current GWAS. These new cases were selected from the larger DILIN sample
collection such that only cases relating to drugs also included among the
iDILIC cases were represented. Laboratory inclusion criteria were as
described previously.<sup><a href="#R16" rid="R16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445484">16</a></sup>
Patients were excluded if there was known or suspected acetaminophen
overdose, if there was a history of bone marrow or liver transplant prior to
DILI onset or if there was a prior history of immune-related liver disease
such as autoimmune hepatitis.</p></div></div><div id="S11" class="sec"><h3 id="S11title">Additional cases used for confirmation of associations</h3><p id="P14" class="p p-first">After the discovery analysis was concluded, we enrolled an additional
283 European patients with diagnosis of DILI across multiple causal drugs (6
from iDILIC and 277 from DILIN networks recruited subsequent to the GWAS). The
causal drug distribution is reported in <a href="#SD1" rid="SD1" class=" supplementary-material">Table S1A</a>. An additional 12 statin DILI samples from the
Spanish iDILIC network and 3 UK-DILIGEN cases were recruited later in the study
to confirm the class specific association (<a href="#SD1" rid="SD1" class=" supplementary-material">Table S1B</a>).</p><p id="P15" class="p p-last">Out of the 283, we used 272 DILI cases to directly type SNPs associated
across multiple drugs or specific for drugs/drug classes and 11 DILI cases for
HLA typing to confirm HLA associations. An additional Chinese terbinafine DILI
sample was also HLA typed.</p></div><div id="S12" class="sec"><h3 id="S12title">Causality assessment</h3><p id="P16" class="p p-first-last">The iDILIC cases were evaluated by application of the Council for
International Organizations of Medical Science (CIOMS) scale, also called the
Roussel Uclaf Causality Assessment Method (RUCAM)<sup><a href="#R15" rid="R15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445486">15</a></sup> and by expert review by a panel of three
hepatologists. The pattern of liver injury was classified according to the
International Consensus Meeting Criteria.<sup><a href="#R17" rid="R17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445520">17</a></sup> Only cases having at least possible causality (score
≥3) were included in the study. For all cases in DILIN, causality
assessment was by expert consensus as previously described.<sup><a href="#R16" rid="R16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445518">16</a></sup></p></div><div id="S13" class="sec"><h3 id="S13title">Controls</h3><p id="P17" class="p p-first-last">Since DILI has a very low prevalence, we used general population samples
as study controls. We selected 10588 European ancestry controls from multiple
available sources; Welcome Trust Case Control Consortium (WTCCC) (<a href="http://www.wtccc.org.uk" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://www.wtccc.org.uk</a>),
the population reference sample (POPRES)<sup><a href="#R18" rid="R18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445483">18</a></sup>, <a id="__tag_670140615" class="tag_hotlink" href="/protein/PGX40001" ref="/protein/PGX40001"><span class="tag-json" style="display:none">{"type":"entrez-protein","attrs":{"text":"PGX40001","term_id":"1265834693","term_text":"PGX40001"}}</span>PGX40001</a><sup><a href="#R19" rid="R19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445546">19</a></sup> and Spanish Bladder cancer cohort (phs000346.v1) from
dbGAP.<sup><a href="#R20" rid="R20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445535">20</a></sup> In order to
increase the case/control ratio for Italian, Spanish and Swedish, we added
samples from Hypergenes cohort (<a href="http://www.hypergenes.eu/dissemination.html#pub" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://www.hypergenes.eu/dissemination.html#pub</a>), the National
Spanish DNA Bank (<a href="http://www.bancoadn.org/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://www.bancoadn.org/</a>), Italian Penicillin Tolerant Controls
(IPTC), and the Swedish Twin Registry (<a href="http://ki.se/en/research/the-swedish-twin-registry" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://ki.se/en/research/the-swedish-twin-registry</a>).</p></div><div id="S14" class="sec"><h3 id="S14title">Genotyping</h3><div id="S15" class="sec sec-first"><p></p><h4 id="S15title" class="inline">DNA preparation from Phase II cases </h4><p id="P18" class="p p-first-last">For iDILIC cases, DNA was prepared as described
previously.<sup><a href="#R8" rid="R8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445512">8</a></sup> DILIN
DNA was extracted from lymphocytes and stored at the NIDDK biosample
repository at Rutgers University, Piscataway, NJ.</p></div><div id="S16" class="sec"><p></p><h4 id="S16title" class="inline">Genome-wide analysis </h4><p id="P19" class="p p-first-last">Genome-wide genotyping of the phase II and 150 phase I cases was
performed by the Broad Institute, Boston by Illumina Infinium HumanCoreExome
BeadChip. iDILIC and DILIN cases were genotyped in two separate batches. A
total of 505740 markers shared across the batches passed quality control
(QC) and no samples were excluded for low quality profile. (see <a href="#SD1" rid="SD1" class=" supplementary-material">Supplemental Materials and
Methods</a>). Details on the genotype data available for each control
collection are reported in <a href="#SD1" rid="SD1" class=" supplementary-material">Table S2</a>.</p></div><div id="S17" class="sec"><p></p><h4 id="S17title" class="inline">Imputation </h4><p id="P20" class="p p-first-last">SNP imputation was performed in batches dividing the cohorts
according to genotyping platforms. Imputation methods are described in
detail in the <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Appendix</a>. For HLA genotypes, four digit HLA
alleles were inferred using HIBAG.<sup><a href="#R21" rid="R21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445528">21</a></sup></p></div><div id="S18" class="sec"><p></p><h4 id="S18title" class="inline">SNP genotyping </h4><p id="P21" class="p p-first-last">The top associated imputed SNPs were validated by SNP genotyping in
subsets of iDILIC cases and in the overall DILIN cohort (see <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary
Appendix</a>). The SNPs were further confirmed in additional cases
using TaqMan<sup>®</sup> predesigned and custom SNP genotyping assays
(ThermoFisher Scientific, Waltham, MA) in accordance with the
manufacturer's recommendations.</p></div><div id="S19" class="sec sec-last"><p></p><h4 id="S19title" class="inline">HLA genotyping </h4><p id="P22" class="p p-first-last">High resolution genotyping of <em>HLA-A</em>,
<em>B</em>, <em>C</em>, <em>DRB1</em>,
<em>DQA1</em> and <em>DQB1</em> was performed on
selected cases by Histogenetics (Ossining, New York). Sequencing data files
were analyzed using Histogenetics’ proprietary analysis software
(Histomatcher and HistoMagic) for HLA genotype calling. Allele assignments
are based on IMGT/HLA Database release version 2.21.0, dated April 2008
(<a href="http://www.ebi.ac.uk/imgt/hla/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://www.ebi.ac.uk/imgt/hla/</a>).</p></div></div><div id="S20" class="sec sec-last"><h3 id="S20title">Statistical analysis</h3><p id="P23" class="p p-first-last">The effect of population structure was assessed through principal
components analysis (PCA) using the smartPCA program from the EIGENSTRAT package
(version 3.0).<sup><a href="#R22" rid="R22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445540">22</a></sup> Single marker
and haplotype association analyses and heterogeneity test analyses were carried
out by PLINK.<sup><a href="#R23" rid="R23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445538">23</a></sup> The
statistical association of each marker, HLA alleles and SNPs, was determined in
a logistic regression framework with scores for the first seven principal
components as covariates under an additive model using PLINK. We used the same
statistical test for sub-population analyses, using two, seven and ten most
significant principal components as covariates in Italian, Spanish and North
European populations, respectively. We set the genome-wide traditional
significance <em>p</em>-value threshold to
5.0×10<sup>−8</sup> to correct for multiple testing.<sup><a href="#R24" rid="R24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445499">24</a></sup> When we obtained genome-wide
significant signals, we tested for independent effects from the neighboring
variants by including the most associated variants as a covariate and then
testing the significance of others in the region. We also tested interaction
effects among them by including interaction terms in the logistic regression.
Differences in clinical characteristics among sample groups were tested by
Fisher's exact test. All detailed analyses and Manhattan plots were
performed with R (Version 3.0.2).<sup><a href="#R25" rid="R25" class=" bibr popnode">25</a></sup> Regional plots were drawn by LocusZoom.<sup><a href="#R26" rid="R26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445545">26</a></sup></p></div></div><div id="S21" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S21title">Results</h2><div id="S22" class="sec sec-first"><h3 id="S22title">Clinical characteristics of the cases</h3><p id="P24" class="p p-first-last">Clinical details of the DILI cases included in the main GWAS are
summarized in <a href="/pmc/articles/PMC5367948/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>. A variety of
different causative drugs were represented but the most common was diclofenac
with 67 cases, followed by nitrofurantoin with 64 cases. A few drugs, including
azathioprine, isoniazid, fenofibrate, and diclofenac had significantly
disproportionate number of cases in one of the two recruitment phases. Details
of all the causative drugs are shown in <a href="#SD1" rid="SD1" class=" supplementary-material">Table S3</a>.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T1"><h3>Table 1</h3><!--caption a7--><div class="caption"><p id="__p20">Clinical details of the DILI cases included in the GWAS</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139620997479104" class="xtable"><table frame="void" rules="none" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1" valign="top" align="left">CHARACTERISTICS</th><th rowspan="1" colspan="1" valign="top" align="left">Phase 1<br>(n=411)</th><th rowspan="1" colspan="1" valign="top" align="left">Phase 2<br>(n=451)</th><th rowspan="1" colspan="1" valign="top" align="left">Combined<br>(n=862)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="top" align="left">
<span class="underline">Clinical information</span>
</td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Age (mean years)</td><td rowspan="1" colspan="1" valign="top" align="left">51</td><td rowspan="1" colspan="1" valign="top" align="left">54</td><td rowspan="1" colspan="1" valign="top" align="left">53</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">% Female</td><td rowspan="1" colspan="1" valign="top" align="left">63.0%</td><td rowspan="1" colspan="1" valign="top" align="left">60.5%</td><td rowspan="1" colspan="1" valign="top" align="left">61.8%</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">ALT (mean IU/L)</td><td rowspan="1" colspan="1" valign="top" align="left">895.1</td><td rowspan="1" colspan="1" valign="top" align="left">757.7</td><td rowspan="1" colspan="1" valign="top" align="left">822.2</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">ALP (mean IU/L)</td><td rowspan="1" colspan="1" valign="top" align="left">388.2</td><td rowspan="1" colspan="1" valign="top" align="left">282.5</td><td rowspan="1" colspan="1" valign="top" align="left">330.6</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Latency (mean days)</td><td rowspan="1" colspan="1" valign="top" align="left">201.7</td><td rowspan="1" colspan="1" valign="top" align="left">177.4</td><td rowspan="1" colspan="1" valign="top" align="left">188.2</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">
<span class="underline">Injury type</span>
</td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Cholestatic</td><td rowspan="1" colspan="1" valign="top" align="left">76</td><td rowspan="1" colspan="1" valign="top" align="left">87</td><td rowspan="1" colspan="1" valign="top" align="left">163</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Hepatocellular</td><td rowspan="1" colspan="1" valign="top" align="left">202</td><td rowspan="1" colspan="1" valign="top" align="left">272</td><td rowspan="1" colspan="1" valign="top" align="left">474</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Mixed</td><td rowspan="1" colspan="1" valign="top" align="left">69</td><td rowspan="1" colspan="1" valign="top" align="left">91</td><td rowspan="1" colspan="1" valign="top" align="left">160</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Not available<sup>*</sup></td><td rowspan="1" colspan="1" valign="top" align="left">64</td><td rowspan="1" colspan="1" valign="top" align="left">1</td><td rowspan="1" colspan="1" valign="top" align="left">65</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">
<span class="underline">Genotype chip</span>
</td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Illumina 1 M</td><td rowspan="1" colspan="1" valign="top" align="left">261</td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left">261</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Illumina 1M/Illumina Infinium
HumanCoreExome<br>BeadChip</td><td rowspan="1" colspan="1" valign="top" align="left">150</td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left">150</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Illumina Infinium HumanCoreExome BeadChip</td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left">447</td><td rowspan="1" colspan="1" valign="top" align="left">447</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Illumina HumanOmniExpress BeadChip</td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left">4</td><td rowspan="1" colspan="1" valign="top" align="left">4</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">
<span class="underline">Country of birth</span>
</td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">USA</td><td rowspan="1" colspan="1" valign="top" align="left">274</td><td rowspan="1" colspan="1" valign="top" align="left">112</td><td rowspan="1" colspan="1" valign="top" align="left">386</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">UK</td><td rowspan="1" colspan="1" valign="top" align="left">71</td><td rowspan="1" colspan="1" valign="top" align="left">79</td><td rowspan="1" colspan="1" valign="top" align="left">150</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Spain</td><td rowspan="1" colspan="1" valign="top" align="left">16</td><td rowspan="1" colspan="1" valign="top" align="left">95</td><td rowspan="1" colspan="1" valign="top" align="left">111</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Sweden</td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left">81</td><td rowspan="1" colspan="1" valign="top" align="left">81</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">France</td><td rowspan="1" colspan="1" valign="top" align="left">30</td><td rowspan="1" colspan="1" valign="top" align="left">7</td><td rowspan="1" colspan="1" valign="top" align="left">37</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Germany</td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left">20</td><td rowspan="1" colspan="1" valign="top" align="left">20</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Italy</td><td rowspan="1" colspan="1" valign="top" align="left">16</td><td rowspan="1" colspan="1" valign="top" align="left">1</td><td rowspan="1" colspan="1" valign="top" align="left">17</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Others</td><td rowspan="1" colspan="1" valign="top" align="left">4</td><td rowspan="1" colspan="1" valign="top" align="left">56</td><td rowspan="1" colspan="1" valign="top" align="left">60</td></tr></tbody></table></div><div id="largeobj_idm139620997479104" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC5367948/table/T1/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="TFN1"><sup>*</sup>Because of the retrospective nature of the phase I study, minimal
clinical information needed to establish the type of injury were not
available for a subset of initial NSAID DILI cases from DILIGEN because of
missing ALP and upper limit of normal values.</div></div></div></div><div id="S23" class="sec"><h3 id="S23title">Overall analysis</h3><p id="P25" class="p p-first">The discovery cohort included 862 European ancestry DILI cases (411 from
phase I<sup><a href="#R12" rid="R12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445505">12</a></sup> and 451 from Phase
II) and 10,588 controls. PCA showed that all cases (including those from South
America) clustered within three major groups (Italian, Spanish and Northern
European) and matched with the population controls (<a href="#SD1" rid="SD1" class=" supplementary-material">Figure S1A</a>). Consistent
with the previous study,<sup><a href="#R12" rid="R12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445507">12</a></sup>
phase I cases were predominantly Northwest European. The most significant
genome-wide associated SNPs were rs72631567 on chromosome 2 (OR=2.0, 95% CI
=1.6-2.5, p-value=9.7×10<sup>−9</sup>) and rs114577328 in the MHC
region of chromosome 6 (OR=2.7, 95% CI=1.9-3.8,
p-value=2.4×10<sup>−8</sup>)(See <a href="/pmc/articles/PMC5367948/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1A</span></a>, <a href="/pmc/articles/PMC5367948/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a> and <a href="#SD1" rid="SD1" class=" supplementary-material">Figures S2</a> and <a href="#SD1" rid="SD1" class=" supplementary-material">S3</a>). Data for both SNPs
had been obtained by imputation in cases and controls and subsequently validated
by SNP typing (see <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Methods</a>). The associations were consistent among
geographic clusters and study phases (<a href="#SD1" rid="SD1" class=" supplementary-material">Table S4</a>) and not due to artefact/s of population
structure, missing genotypes rate (<a href="#SD1" rid="SD1" class=" supplementary-material">Table S5</a>) or variability in imputation quality among
populations or genotyping platforms (see <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Methods</a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F1" co-legend-rid="lgnd_F1"><a href="/pmc/articles/PMC5367948/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139620986084336" class="figure"><a href="/pmc/articles/PMC5367948/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=5367948_nihms-840066-f0001.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is nihms-840066-f0001.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC5367948/bin/nihms-840066-f0001.jpg"></a></div><div id="largeobj_idm139620986084336" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC5367948/figure/F1/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="/pmc/articles/PMC5367948/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Figure 1</a></div><!--caption a7--><div class="caption"><p id="__p18">Manhattan plots displaying the association results of (A) the overall analysis
(n=864); (B) terbinafine only cases (n=14 cases). SNPs in green have a
significance level less than 5×10<sup>−6</sup> and red have a
significance level less than 5×10<sup>−8</sup>.</p></div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T2"><h3>Table 2</h3><!--caption a7--><div class="caption"><p id="__p21">Association effect size of rs72631567, A*33:01 and rs28521457 across different
liver injury patterns</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139620996653440" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1" valign="middle" align="left">COHORTs</th><th rowspan="1" colspan="1" valign="middle" align="center">Variant</th><th rowspan="1" colspan="1" valign="middle" align="center">OR</th><th rowspan="1" colspan="1" valign="middle" align="center">95% CI</th><th rowspan="1" colspan="1" valign="middle" align="center">P</th><th rowspan="1" colspan="1" valign="middle" align="center">AF<br>Cases</th><th rowspan="1" colspan="1" valign="middle" align="center">AF<br>Controls</th></tr></thead><tbody><tr><td rowspan="3" colspan="1" valign="middle" align="left">
<strong>Entire</strong>
<br>
<strong>DILI cohort</strong>
</td><td rowspan="1" colspan="1" valign="middle" align="center">
<strong>rs72631567</strong>
</td><td rowspan="1" colspan="1" valign="middle" align="center">2.0</td><td rowspan="1" colspan="1" valign="middle" align="center">1.6-2.5</td><td rowspan="1" colspan="1" valign="middle" align="center">9.7×10<sup>−9</sup></td><td rowspan="1" colspan="1" valign="middle" align="center">0.05</td><td rowspan="1" colspan="1" valign="middle" align="center">0.03</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center">
<strong>A*33:01</strong>
</td><td rowspan="1" colspan="1" valign="middle" align="center">2.6</td><td rowspan="1" colspan="1" valign="middle" align="center">1.8-3.7</td><td rowspan="1" colspan="1" valign="middle" align="center">7.0×10<sup>−8</sup></td><td rowspan="1" colspan="1" valign="middle" align="center">0.02</td><td rowspan="1" colspan="1" valign="middle" align="center">0.01</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center">
<strong>rs28521457</strong>
</td><td rowspan="1" colspan="1" valign="middle" align="center">1.5</td><td rowspan="1" colspan="1" valign="middle" align="center">1.3-1.9</td><td rowspan="1" colspan="1" valign="middle" align="center">5.1×10<sup>−5</sup></td><td rowspan="1" colspan="1" valign="middle" align="center">0.06</td><td rowspan="1" colspan="1" valign="middle" align="center">0.04</td></tr><tr><td colspan="7" rowspan="1" valign="middle" align="left">
<hr>
</td></tr><tr><td rowspan="3" colspan="1" valign="middle" align="left">
<strong>Cholestatic</strong>
<br>
<strong>and Mixed</strong>
<br>
<strong>DILI cohort</strong>
</td><td rowspan="1" colspan="1" valign="middle" align="center">
<strong>rs72631567</strong>
</td><td rowspan="1" colspan="1" valign="middle" align="center">2.4</td><td rowspan="1" colspan="1" valign="middle" align="center">1.7-3.4</td><td rowspan="1" colspan="1" valign="middle" align="center">9.5×10<sup>−7</sup></td><td rowspan="1" colspan="1" valign="middle" align="center">0.06</td><td rowspan="1" colspan="1" valign="middle" align="center">0.03</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center">
<strong>A*33:01</strong>
</td><td rowspan="1" colspan="1" valign="middle" align="center">5.0</td><td rowspan="1" colspan="1" valign="middle" align="center">3.3-7.9</td><td rowspan="1" colspan="1" valign="middle" align="center">4.2×10<sup>−13</sup></td><td rowspan="1" colspan="1" valign="middle" align="center">0.04</td><td rowspan="1" colspan="1" valign="middle" align="center">0.01</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center">
<strong>rs28521457</strong>
</td><td rowspan="1" colspan="1" valign="middle" align="center">1.0</td><td rowspan="1" colspan="1" valign="middle" align="center">0.7-1.5</td><td rowspan="1" colspan="1" valign="middle" align="center">0.9</td><td rowspan="1" colspan="1" valign="middle" align="center">0.04</td><td rowspan="1" colspan="1" valign="middle" align="center">0.04</td></tr><tr><td colspan="7" rowspan="1" valign="middle" align="left">
<hr>
</td></tr><tr><td rowspan="3" colspan="1" valign="middle" align="left">
<strong>Hepatocellular</strong>
<br>
<strong>DILI cohort</strong>
</td><td rowspan="1" colspan="1" valign="middle" align="center">
<strong>rs72631567</strong>
</td><td rowspan="1" colspan="1" valign="middle" align="center">1.6</td><td rowspan="1" colspan="1" valign="middle" align="center">1.2-2.3</td><td rowspan="1" colspan="1" valign="middle" align="center">2.5×10<sup>−3</sup></td><td rowspan="1" colspan="1" valign="middle" align="center">0.04</td><td rowspan="1" colspan="1" valign="middle" align="center">0.03</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center">
<strong>A*33:01</strong>
</td><td rowspan="1" colspan="1" valign="middle" align="center">1.5</td><td rowspan="1" colspan="1" valign="middle" align="center">0.8-2.6</td><td rowspan="1" colspan="1" valign="middle" align="center">0.19</td><td rowspan="1" colspan="1" valign="middle" align="center">0.01</td><td rowspan="1" colspan="1" valign="middle" align="center">0.011</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center">
<strong>rs28521457</strong>
</td><td rowspan="1" colspan="1" valign="middle" align="center">2.1</td><td rowspan="1" colspan="1" valign="middle" align="center">1.6-2.7</td><td rowspan="1" colspan="1" valign="middle" align="center">4.8×10<sup>−9</sup></td><td rowspan="1" colspan="1" valign="middle" align="center">0.08</td><td rowspan="1" colspan="1" valign="middle" align="center">0.040</td></tr></tbody></table></div><div id="largeobj_idm139620996653440" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC5367948/table/T2/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="TFN2"><p id="P90" class="p p-first-last">COHORTs = type of comparison; Variant = associated variant; OR=Odds
Ratio; 95% CI = 95% Confidence Interval of the odds ratio; P=logistic
p-value; AF = allele frequency</p></div></div></div><p id="P26">For the chromosome 2 SNP rs72631567, breakdown by drug showed that 10
unrelated drug causes had an OR greater than 2.0 with at least two carriers
(<a href="#SD1" rid="SD1" class=" supplementary-material">Table S6</a>).
Ciprofloxacin-related cases showed the strongest association (n=21, OR=7.4, 95%
CI=17.3-161, p-value = 4.0×10<sup>−6</sup>).</p><p id="P27">The chromosome 6 SNP rs114577328 is the SNP proxy of an uncommon HLA
class I allele, HLA-A*33:01. Indeed this SNP was in near-perfect LD with A*33:01
(r<sup>2</sup>=0.98). From the imputed HLA allele assignments, a strong
association with DILI for this allele is confirmed (OR=2.6; 95% CI=1.8-3.7,
p-value=8.0×10<sup>−8</sup>, <a href="#SD1" rid="SD1" class=" supplementary-material">Figure S4</a>). Including
rs114577328 or A*33:01 as a covariate removed any association in the MHC region,
indicating that there is only one MHC association signal (<a href="#SD1" rid="SD1" class=" supplementary-material">Figure S5</a>). The A*33:01
association appears independent of the chromosome 2 signal, since rs72631567
when conditioned on A*33:01 showed an almost unchanged effect size
(OR<sub>rs72631567</sub> = 1.7, 95% CI= 1.25-2.2, p-value = 0.0006). There
was no statistically significant interaction effect between the two signals
(p-value = 0.5).</p><p id="P28">Breakdown by drug showed DILI due to terbinafine was most strongly
associated with the HLA-A*33:01 signal (OR=40.5, 95% CI=12.5-131.4,
p-value=6.7×10<sup>−10</sup>) and a similarly strong
association was seen with rs114577328 (OR=58.7, 95% CI=18.31-188.2,
p-value=7.3×10<sup>−12</sup>, <a href="/pmc/articles/PMC5367948/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1B</span></a> and <a href="#SD1" rid="SD1" class=" supplementary-material">Figure S6</a>). As summarized in <a href="/pmc/articles/PMC5367948/table/T3/" target="table" class="fig-table-link figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span>Table
3</span></a>, in addition to terbinafine cases, cases due to six additional
drugs showed an association with A*33:01 with p-values lower than 0.01. The
largest case subset related to terbinafine but we found that A*33:01 was also a
risk factor for ticlopidine (OR=163.1, 95% CI=16.2-1642.0, p-value=0.00002),
methyldopa (OR=97.8, 95% CI=12.3-743.0, p-value=0.00001) and fenofibrate DILI
(OR=58.7; 95% CI=12.3-279.8; p-value=3.2×10<sup>−7</sup>). Indeed,
although fewer positive carriers were observed, A*33:01 also seems to be a
common risk factor for enalapril (OR=34.8), sertraline (OR=29) and erythromycin
DILI (OR=10.2). An erythromycin case was positive for A*33:03, an allele rare in
European population controls (AF=0.002) which belongs to the A*33 group. Overall
we found that 87% (n=36) of the A*33:01 positive carriers were also positive for
HLA-B*14:02 and HLA-C*08:02. The haplotype showed a larger OR than A*33:01 as
single marker in terbinafine (OR<sub>haplotype</sub> =49.2,
p-value=9.54×10<sup>−11</sup>), ticlopidine
(OR<sub>haplotype</sub> =201; p-value= 7.2×10<sup>−6</sup>),
fenofibrate (OR<sub>haplotype</sub> 68.5;
p-value=1.1×10<sup>−7</sup>) and erythromycin
(OR<sub>haplotype</sub> = 13.1; p-value=0.002) DILI but not with DILI as a
phenotype (OR<sub>haplotype</sub> =2.7; p-value=
1.6×10<sup>−7</sup>, <a href="#SD1" rid="SD1" class=" supplementary-material">Table S7</a>).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T3"><h3>Table 3</h3><!--caption a7--><div class="caption"><p id="__p22">Association effect size of A*33:01 signal for the causal drugs enriched in
A*33:01 positive carriers</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139620994858720" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1" valign="middle" align="left">DRUGs</th><th rowspan="1" colspan="1" valign="middle" align="center">Number<br>of cases<br>tested</th><th rowspan="1" colspan="1" valign="middle" align="center">Number<br>of<br>A*33:01<br>alleles<br>in cases</th><th rowspan="1" colspan="1" valign="middle" align="center">OR</th><th rowspan="1" colspan="1" valign="middle" align="center">95% CI</th><th rowspan="1" colspan="1" valign="middle" align="center">P</th><th rowspan="1" colspan="1" valign="middle" align="center">CF</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="middle" align="left">
<strong>TICLOPIDINE</strong>
</td><td rowspan="1" colspan="1" valign="middle" align="center">5</td><td rowspan="1" colspan="1" valign="middle" align="center">4</td><td rowspan="1" colspan="1" valign="middle" align="center">163.1</td><td rowspan="1" colspan="1" valign="middle" align="center">16.2-<br>1642</td><td rowspan="1" colspan="1" valign="middle" align="center">0.00002</td><td rowspan="1" colspan="1" valign="middle" align="center">0.8</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="left">
<strong>METHYLDOPA</strong>
</td><td rowspan="1" colspan="1" valign="middle" align="center">4</td><td rowspan="1" colspan="1" valign="middle" align="center">2</td><td rowspan="1" colspan="1" valign="middle" align="center">97.8</td><td rowspan="1" colspan="1" valign="middle" align="center">12.8-<br>743.8</td><td rowspan="1" colspan="1" valign="middle" align="center">0.00001</td><td rowspan="1" colspan="1" valign="middle" align="center">0.5</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="left">
<strong>FENOFIBRATE</strong>
</td><td rowspan="1" colspan="1" valign="middle" align="center">7</td><td rowspan="1" colspan="1" valign="middle" align="center">4</td><td rowspan="1" colspan="1" valign="middle" align="center">58.7</td><td rowspan="1" colspan="1" valign="middle" align="center">12.3-<br>279.8</td><td rowspan="1" colspan="1" valign="middle" align="center">3.2*10<sup>−7</sup></td><td rowspan="1" colspan="1" valign="middle" align="center">0.43</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="left">
<strong>TERBINAFINE</strong>
</td><td rowspan="1" colspan="1" valign="middle" align="center">14</td><td rowspan="1" colspan="1" valign="middle" align="center">6</td><td rowspan="1" colspan="1" valign="middle" align="center">40.5</td><td rowspan="1" colspan="1" valign="middle" align="center">12.5-<br>131.4</td><td rowspan="1" colspan="1" valign="middle" align="center">6.7*10<sup>−10</sup></td><td rowspan="1" colspan="1" valign="middle" align="center">0.43</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="left">
<strong>ENALAPRIL</strong>
</td><td rowspan="1" colspan="1" valign="middle" align="center">4</td><td rowspan="1" colspan="1" valign="middle" align="center">2</td><td rowspan="1" colspan="1" valign="middle" align="center">34.8</td><td rowspan="1" colspan="1" valign="middle" align="center">3.9-302.9</td><td rowspan="1" colspan="1" valign="middle" align="center">0.001</td><td rowspan="1" colspan="1" valign="middle" align="center">0.5</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="left">
<strong>SERTRALINE</strong>
</td><td rowspan="1" colspan="1" valign="middle" align="center">5</td><td rowspan="1" colspan="1" valign="middle" align="center">2</td><td rowspan="1" colspan="1" valign="middle" align="center">29</td><td rowspan="1" colspan="1" valign="middle" align="center">4-207.2</td><td rowspan="1" colspan="1" valign="middle" align="center">0.0008</td><td rowspan="1" colspan="1" valign="middle" align="center">0.4</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="left">
<strong>ERYTHROMYCIN</strong>
</td><td rowspan="1" colspan="1" valign="middle" align="center">10</td><td rowspan="1" colspan="1" valign="middle" align="center">2</td><td rowspan="1" colspan="1" valign="middle" align="center">10.2</td><td rowspan="1" colspan="1" valign="middle" align="center">2-51.7</td><td rowspan="1" colspan="1" valign="middle" align="center">0.005</td><td rowspan="1" colspan="1" valign="middle" align="center">0.2</td></tr></tbody></table></div><div id="largeobj_idm139620994858720" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC5367948/table/T3/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="TFN3"><p id="P91" class="p p-first-last">DRUGs=Causal drug involved; OR=Odds Ratio; 95% CI = 95% Confidence
Interval of the odds ratio; P=logistic p-value; CF= Carrier Frequency</p></div></div></div><p id="P29" class="p p-last">We verified the imputed A*33:01 genotype by sequence-based HLA typing in
35 cases related to the main A*33:01-associated drugs (<a href="#SD1" rid="SD1" class=" supplementary-material">Table S8</a>). The A*33:01
predictions were confirmed in all cases except that one methyldopa case was
negative for this allele (false positive) and an additional terbinafine case was
a carrier (false negative). This validation result suggests that methyldopa
might not share the HLA risk factor. The validation confirmed that all the
A*33:01-positive terbinafine cases carried the complete HLA
A*33:01-B*14:02-C*08:02 haplotype, increasing the strength of the haplotype
association in the terbinafine DILI cases (OR<sub>haplotype</sub>=70;
p-value=8.7×10<sup>−13</sup>) and in the overall analyses
(OR<sub>haplotype</sub>=2.8; p-value=5.1×10<sup>−8</sup>). We
also typed the A*33:01 proxy SNP across DILIN cases to confirm imputed
genotypes. We found only one new carrier of the minor allele, not related to the
major-A*33:01 associated drugs.</p></div><div id="S24" class="sec"><h3 id="S24title">Analysis by type of injury and causative drugs</h3><p id="P30" class="p p-first">We further investigated the association of genotypes with particular
patterns of DILI by grouping the cases into hepatocellular (HC) and
cholestatic/mixed (CM) pattern. The chromosome 2 association described above was
similar in the two phenotypic categories (direct comparison between CM cases vs
HC cases, logistic p-value=0.5), although the effect was marginally stronger in
the CM cases (<a href="/pmc/articles/PMC5367948/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>). The association
with rs114577328 was genome-wide significant only in the CM cases (n=323,
OR=5.3, 95% CI=3.4-8.2, p-value=4.5×10<sup>−14</sup>, <a href="/pmc/articles/PMC5367948/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2B</span></a> and <a href="#SD1" rid="SD1" class=" supplementary-material">Figure S6</a>) and similarly
with A*33:01 (OR=5.1; 95% CI=3.3-7.9,
p-value=4.2×10<sup>−13</sup>, <a href="/pmc/articles/PMC5367948/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure
2B</span></a> and <a href="#SD1" rid="SD1" class=" supplementary-material">Figure
S6</a>). Conditional analysis on the variant and HLA allele indicated
only one genetic association was present in the region, as shown for the main
analysis (<a href="#SD1" rid="SD1" class=" supplementary-material">Figure S7</a>).
There was no association between the proxy SNP or A*33:01 in the HC cases
(n=474, OR for A*33:01=1.5, 95% CI=0.82-2.6, p-value=0.19, <a href="/pmc/articles/PMC5367948/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>). The A*33:01-B*14:02-C*08:02
haplotype showed an OR<sub>haplotype</sub> = 5.6; p-value =
2.5×10<sup>−13</sup> in CM cases.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F2" co-legend-rid="lgnd_F2"><a href="/pmc/articles/PMC5367948/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139620997745920" class="figure"><a href="/pmc/articles/PMC5367948/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=5367948_nihms-840066-f0002.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is nihms-840066-f0002.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC5367948/bin/nihms-840066-f0002.jpg"></a></div><div id="largeobj_idm139620997745920" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC5367948/figure/F2/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_F2"><div><a class="figpopup" href="/pmc/articles/PMC5367948/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2">Figure 2</a></div><!--caption a7--><div class="caption"><p id="__p19">Manhattan plot displaying the association results for (A) Cholestatic/Mixed only
cases (n=323); (B) Hepatocellular only cases (n=474 cases); (C) Statin cases
(n=59). SNPs in green have a significance level less than
5×10<sup>−6</sup> and red have a significance level less than
5×10<sup>−8</sup>.</p></div></div></div><p id="P31">The CM only terbinafine-specific OR increased two fold compared with the
value for all terbinafine cases (OR=88.1, 95% CI = 19.3-402.4, p-value =
7.5×10<sup>−9</sup>) since all the A*33:01 carriers belonged
to this injury type. Following the injury correlation pattern established for
terbinafine, A*33:01 appeared to be a stronger risk factor for CM injury than
for HC injury also for fenofibrate, ticlopidine, enalapril and
erythromycin-related DILI. This was not the case for injury due to sertraline
and methyldopa. These top seven drugs account for 51% (n=21) of all A*33:01
positive cases (<a href="#SD1" rid="SD1" class=" supplementary-material">Table
S9</a>). Sixteen other drugs account for the rest of the carriers showing
slight enrichment in CM phenotypes, which showed a marginal association with
A*33:01 (OR = 2.6, 95% CI = 1.4-4.9, p-value = 0.003, <a href="#SD1" rid="SD1" class=" supplementary-material">Table S9</a> and <a href="#SD1" rid="SD1" class=" supplementary-material">Table S10</a>).</p><p id="P32">We detected a new HC-specific genome-wide significant signal on
chromosome 4 (<a href="/pmc/articles/PMC5367948/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2B</span></a>). The signal lies
within the <em>LRBA</em> (LPS-responsive vesicle trafficking, beach and
anchor containing) gene with the imputed variant rs28521457, located in an
intronic region, the most significant SNP (OR=2.1, 95% CI=1.6-2.7,
p-value=4.8×10<sup>−9</sup>)(<a href="/pmc/articles/PMC5367948/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a> and <a href="/pmc/articles/PMC5367948/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2B</span></a>). The
allele frequency for this SNP in the CM cases (0.04) was comparable to that in
controls with no evidence of association with this phenotype. The risk allele
was carried by more than 4% of the HC cases in cases due to a total of 45 drugs
but in general, there were no drug-specific signals (<a href="#SD1" rid="SD1" class=" supplementary-material">Table S11</a>).</p><p id="P33" class="p p-last">We also investigated associations with particular causative drugs or
specific therapeutic classes where a group including more than 40 samples was
available. Detail on the groups studied is summarized in <a href="#SD1" rid="SD1" class=" supplementary-material">Table S12</a>. Genome-wide
significance was detected only for one group examined, the statins, with no
significant signals for the other drug classes (<a href="#SD1" rid="SD1" class=" supplementary-material">Figure S8</a> and <a href="#SD1" rid="SD1" class=" supplementary-material">Table S13</a>). In the case
of the statins, rs116561224, a common intergenic SNP on chromosome 18, was
genome-wide significant (OR=5.4, 95% CI=3.0-9.5,
p-value=7.1×10<sup>−9</sup>, <a href="/pmc/articles/PMC5367948/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2C</span></a> and <a href="#SD1" rid="SD1" class=" supplementary-material">Figure S9</a>) with the signal mainly driven by simvastatin (<a href="#SD1" rid="SD1" class=" supplementary-material">Table S14</a>).</p></div><div id="S25" class="sec sec-last"><h3 id="S25title">Confirmation of associations</h3><p id="P34" class="p p-first">The European cohort used to confirm the associations (n=283) had a wider
range of causal drugs, mostly different from the discovery cohort (<a href="#SD1" rid="SD1" class=" supplementary-material">Table S1</a>). Later in time,
we had access to 15 additional cases relating specifically to the statin
cohort.</p><p id="P35">The A*33:01 association was further investigated in the additional cases
by directly genotyping rs114577328 in 272 cases and by direct HLA typing on 11
additional samples who developed DILI due to drugs for which we had detected an
enrichment in A*33:01 alleles in the discovery cases. Overall, the rs114577328
carriers were enriched in cases from drugs previously associated with the allele
(<a href="#SD1" rid="SD1" class=" supplementary-material">Table S15</a>). Eight
out of all 23 additional cases relating to drugs previously associated with
A*33:01 were shown to carry this allele or the proxy SNP (allele frequency 0.17)
compared with an expected population frequency of 0.01. We specifically
confirmed the association of A*33:01/rs114577328 with terbinafine having a
carrier frequency of 0.63 (5 out 8 terbinafine-related cases across both the
injury types) and with sertraline at a carrier frequency of 0.75 (3 out 4
sertraline-related cases) (<a href="#SD1" rid="SD1" class=" supplementary-material">Table S15</a>). Although fenofibrate had a high carriage rate for
A*33:01 in the discovery cohort, none of the 7 additional cases carried this
allele or the proxy SNP. Few additional cases were available for other
A*33:01-related drugs to confirm the association.</p><p id="P36">Interestingly, a terbinafine DILI case from Finland was positive for
A*33:05, a very rare allele in the general European population (AF = 0.0001,
<em>USA NMDP European Caucasian</em> in <a href="http://www.allelefrequencies.net/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://www.allelefrequencies.net/</a>, n=1,242,890) and
Finnish<sup><a href="#R27" rid="R27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445487">27</a></sup> populations.
An additional terbinafine DILI case of Chinese origin was positive for A*33:03.
In total, 10 of the 24 additional cases (23 European cases and one single
Chinese case) were carriers of an A*33 allele, in line with expectations based
on the effects observed in the discovery sample.</p><p id="P37">We further genotyped rs72631567 and rs28521457 in 272 additional
European cases. The rs72631567 and rs28521457 variants were found at AFs
comparable to those for controls (AF<sub>rs72631567</sub> = 0.022 and
AF<sub>rs28521457</sub> in HC only = 0.025) and so the association was not
confirmed. However, rs72631567 carriers were slightly enriched in ciprofloxacin,
atorvastatin and mercaptopurine-induced DILI cases, as in the discovery cohort,
with ORs in the same direction in both cohorts (<a href="#SD1" rid="SD1" class=" supplementary-material">Table S16</a>). Similarly,
rs28521457 carriers seemed to be more common in the same subgroup of causal
drugs in both cohorts (<a href="#SD1" rid="SD1" class=" supplementary-material">Table
S17</a>). This suggested a limited replication of the signal for these
drugs.</p><p id="P38" class="p p-last">We also attempted to confirm the rs116561224 signal for statins. The
number of additional cases available for this purpose was small (n=29, <a href="#SD1" rid="SD1" class=" supplementary-material">Table S1b</a>) with only four
simvastatin cases. None of the statin cases were positive for rs116561224 so the
signal could not be confirmed.</p></div></div><div id="S26" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S26title">Discussion</h2><p id="P39" class="p p-first">Our previous studies have been successful in identifying genetic risk
factors for both flucloxacillin and amoxicillin-clavulanate DILI.<sup><a href="#R4" rid="R4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445516">4</a>, <a href="#R6" rid="R6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445517">6</a></sup> However, our most recent GWAS did not identify any risk factors
that were common for DILI in general or specific genetic risk factors for DILI due
to individual drugs which accounted for a smaller number of cases of DILI.<sup><a href="#R12" rid="R12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445508">12</a></sup> The current study included 451
additional cases of DILI due to a wide variety of causative drugs, including at
least 10 DILI cases relating to each of 22 different drugs. This increase in numbers
and the exclusion of the amoxicillin-clavulanate and flucloxacillin cases together
with use of improved imputation methods has enabled the detection and confirmation
of a novel genome-wide significant signal relating to a relatively rare HLA class I
allele A*33:01. Though three other interesting signals were detected in the course
of the study, an intergenic signal on chromosome 2, an intronic SNP in
<em>LRBA</em> in HC cases only and a signal on chromosome 18 for
statins, the failure to confirm these signals is a limitation. There are some
indications that, as observed for HLA-A*33:01, the chromosome 2 and LRBA signals are
shared across multiple unrelated drugs instead of being non-drug-specific risk
variants. As supporting evidence, the chromosome 2 signal has been consistently
associated in both replication and discovery cohorts with DILI due to ciprofloxacin,
atorvastatin and mercaptopurine. There remains a possibility that replication could
be achieved in a larger study involving a different mix of causative drugs but the
degree of heterogeneity in drugs originally associated with the signals also
increases the risk that these were chance observations.</p><p id="P40">Interestingly, unlike previously recognized HLA associations for DILI,
A*33:01 also appears to be a risk factor for DILI due to several, structurally
unrelated drugs. Our results also suggest that a haplotype comprising A*33:01,
B*14:02, and C*08:02 may participate in concert to confer risk for DILI, as opposed
to A*33:01 alone. However, because these alleles are so highly correlated, our
current sample size does not allow us to distinguish between these possible
explanations by genetic association evidence alone. This conceivable hypothesis
could be further verified in a larger study, or by experiments with recombinant HLA
proteins.<sup><a href="#R28" rid="R28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445548">28</a></sup></p><p id="P41">In the case of terbinafine where the A*33:01 association showed genome-wide
significance for cases relating to this drug only, information on the underlying
mechanism for hepatotoxicity is limited, <em>N</em>-dealkylation leads to
the formation of an aldehyde metabolite, TBF-A, and this metabolite shows reactivity
with glutathione.<sup><a href="#R29" rid="R29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445498">29</a></sup> It has been
proposed that the GSH-adduct is transported across the canalicular membrane and
concentrated in the bile where it may cause damage to biliary epithelial cells.
There is limited data from the various case reports on an underlying inflammatory
mechanism but it has been demonstrated that treatment of monocytes with terbinafine
results in the release of the proinflammatory cytokines IL-8 and
TNF-alpha.<sup><a href="#R30" rid="R30" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445536">30</a></sup> Metabolism of
terbinafine is complex involving several different cytochromes P450.<sup><a href="#R31" rid="R31" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445543">31</a></sup> However, there was no evidence
from the GWAS for a role for either CYP genes or innate immunity genes in the
terbinafine DILI cases studied.</p><p id="P42">The other drugs showing the most convincing associations with A*33:01 were
fenofibrate, ticlopidine and sertraline. Failure to see individual genome-wide
significant associations with these drugs is likely to be due to fewer cases being
available than for terbinafine. The A*33:01 association was seen for 3 of 7 cases
due to fenofibrate, all with CM DILI. The literature on fenofibrate DILI is quite
limited, but it appears that this drug is extensively metabolized, mainly by
CYP3A4,<sup><a href="#R32" rid="R32" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445511">32</a></sup> and there is a
report of a drug interaction resulting in cholestatic injury<sup><a href="#R33" rid="R33" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445542">33</a></sup> together with other isolated
reports of idiosyncratic cholestatic DILI.<sup><a href="#R34" rid="R34" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445527">34</a></sup></p><p id="P43">Ticlopidine-related DILI has been well studied previously, including two
studies investigating genetic risk factors in Japanese individuals. Cholestatic
liver injury also predominates in this form of DILI.<sup><a href="#R35" rid="R35" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445489">35</a>, <a href="#R36" rid="R36" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445488">36</a></sup>
Ticlopidine is subject to extensive metabolism by several cytochrome P450 isoforms
and carboxyesterase.<sup><a href="#R37" rid="R37" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445482">37</a></sup> A study in
rats suggests that adducts are formed following metabolism by cytochrome P450 with
evidence for toxicity after biliary excretion of glutathione-conjugated metabolites
via MRP2-facilitated transport.<sup><a href="#R38" rid="R38" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445525">38</a></sup>
In previous studies, 22 Japanese patients with ticlopidine DILI showed an
association with an HLA haplotype including A*33:03 (odds ratio 13).<sup><a href="#R39" rid="R39" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445532">39</a></sup> In line with current observations,
the association was strongest with cholestatic cases with 12 out of 14 cases
positive for A*33:03. It should be noted that A*33:03 is relatively common in Japan
with approximately 10 to 15% of individuals carrying this allele.</p><p id="P44">The observations on the HLA association for Japanese ticlopidine DILI cases
were followed up by a report that those carrying a −2320T&gt;C
polymorphism in <em>CYP2B6</em> were more susceptible to ticlopidine DILI
due to high CYP2B6 expression (OR 2, p-value=0.04).<sup><a href="#R40" rid="R40" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445519">40</a></sup> The <em>CYP2B6</em> polymorphism
(rs7254579)<sup><a href="#R41" rid="R41" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445541">41</a></sup> is less
frequent in Europeans than in Asians (MAF<sub>cau</sub> = 0.29, MAF<sub>asian</sub>
= 0.45) and its low effect size limited our ability to replicate the association in
this small European ticlopidine DILI population, but the non-significant effect is
in the same direction as the previous study (OR=2.8, 95% CI=0.7-10.18,
p-value=0.11).</p><p id="P45">In contrast with the three drug examples above, sertraline is associated
predominantly with HC DILI.<sup><a href="#R42" rid="R42" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445480">42</a>-<a href="#R44" rid="R44" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598725207">44</a></sup> In line with this phenotypic
association, there is evidence that sertraline can cause mitochondrial
damage<sup><a href="#R28" rid="R28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445503">28</a></sup> and induce
endoplasmic reticulum stress<sup><a href="#R45" rid="R45" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_656162973">45</a></sup> in
liver cells. There are parallels with a previous example of a HLA risk factor
(DRB1*15:01) which is associated with predominantly CM DILI with
amoxicillin-clavulanate but HC DILI with lumiracoxib.<sup><a href="#R9" rid="R9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445495">9</a>, <a href="#R10" rid="R10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445531">10</a></sup></p><p id="P46">In line with the Japanese report of a role for A*33:03 in ticlopidine
DILI<sup><a href="#R39" rid="R39" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445521">39</a></sup> and a case report
showing an association between A*33 and tiopronin-induced cholestasis in a Chinese
patient,<sup><a href="#R46" rid="R46" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445534">46</a></sup> we found two
DILI cases positive for A*33:03 after direct HLA typing. One of these was a Chinese
terbinafine DILI case and the second a European-American with erythromycin DILI. In
our imputed GWAS dataset, <em>A*33:03</em> was carried by eight DILI cases
due to a range of drugs in our cohort and showed an apparent risk effect for CM DILI
but this was not genome-wide significant (OR=2.1, 95% CI=1.02-4.6, p-value=0.04).
Another A*33 allele, A*33:05, was also represented in a terbinafine case from
Finland. There is very strong homology between these three HLA-A*33 alleles at the
protein sequence level with <em>A*33:03</em> differing at only two positions
from A*33:01 (Tyr instead of His at position 171 and Lys instead of Arg at position
186) and A*33:05 differing at only one position (Arg at 54 in place of Gln). In
particular, all three alleles conserve the key residues for specific peptide binding
within the B and F pockets.<sup><a href="#R47" rid="R47" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445490">47</a></sup> This
is in contrast to a related HLA allele A*31:01, which is associated with
carbamazepine-induced skin rash,<sup><a href="#R48" rid="R48" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445504">48</a></sup>
but does not appear to be a risk factor for DILI, where the B pocket sequence,
though homologous, is not conserved.<sup><a href="#R47" rid="R47" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445494">47</a></sup></p><p id="P47">As mentioned above, the association of a common HLA allele with DILI due to
chemically-unrelated compounds had been observed previously for DRB1*15:01<sup><a href="#R10" rid="R10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445502">10</a></sup> with amoxicillin-clavulanate and
lumiracoxib and for DRB1*07:01<sup><a href="#R49" rid="R49" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445537">49</a></sup>
with DILI from lapatinib and ximelagatran. The association of A*33:01 with DILI in
general and secondary to a number of structurally dissimilar compounds is consistent
with these observations. Together with recent findings from <em>in
vitro</em> studies on T-cell responses to flucloxacillin and
amoxicillin-clavulanate,<sup><a href="#R50" rid="R50" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445513">50</a>,
<a href="#R51" rid="R51" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445530">51</a></sup> these observations support
the hypothesis that either the parent drug or metabolites bind covalently to
cellular or circulating proteins to form adducts in a mechanism that is probably
slightly different to the direct drug effect seen with hypersensitivity reactions to
abacavir.<sup><a href="#R52" rid="R52" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445544">52</a></sup> Adduct
formation may then allow binding to the peptide binding groove of HLA molecules
leading to activation and differentiation of T-cells with a consequent adaptive
immune response-mediated liver injury. Evidence that the majority of the drugs
showing the A*33:01 association undergo hepatic metabolism and biliary excretion may
explain the stronger association of A*33:01 with CM DILI and could indicate that,
unlike in the case of flucloxacillin and amoxicillin-clavulanate, metabolites
contribute to the toxicity mechanism. Further investigation of potential interaction
of both the various drugs and their metabolites with the A*33:01 gene product by
molecular modelling and <em>in vitro</em> studies on T cells as previously
undertaken for flucloxacillin<sup><a href="#R50" rid="R50" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445529">50</a></sup>
would be of interest.</p><p id="P48">The novel association of HC DILI with <em>LRBA</em> is interesting
because this gene is a biologically plausible DILI candidate. LRBA deficiency due to
rare mutations is associated with primary immunodeficiency of variable severity with
a particular feature of decreased regulatory T cell (Treg) levels, other
immunodeficiencies and inherited autoimmune disease.<sup><a href="#R53" rid="R53" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445493">53</a>-<a href="#R56" rid="R56" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598725206">56</a></sup> Patients
with mutations in LRBA leading to immunodeficiency have been demonstrated to show
loss of cytotoxic T lymphocyte antigen-4 (CTLA4).<sup><a href="#R57" rid="R57" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445515">57</a></sup> Studies in a mouse model suggest that low CTLA4 is
a risk factor for DILI.<sup><a href="#R58" rid="R58" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445496">58</a></sup> Unlike
the HLA-A*33:01 association, no genome-wide significant associations for single
drugs were detected with the <em>LRBA</em> SNP and there were no obvious
features in common between cases positive for the variant other than the HC
phenotype. It remains possible that this association could be replicated if a larger
cohort were available.</p><p id="P49">The intergenic signal on chromosome 2 is from a region 800 kb upstream from
<em>SOX11</em>, is independent of <em>A*33:01</em> and
associated with an almost two-fold risk of DILI with the top SNP showing a frequency
of 0.02 in Europeans. This risk factor seems to be shared across unrelated drugs
among which ciprofloxacin showed the strongest association. The ENCODE project
suggests there are no regulatory elements in this region so the basis for the signal
is unclear. Neither rs72631567 nor any of its LD SNPs (r<sup>2</sup>&gt;0.5) are
known eQTL variants (<a href="http://www.gtexportal.org/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://www.gtexportal.org/</a>). The failure to confirm this association
and the absence of any apparent biological basis suggests the observed significance
could have been a chance finding.</p><p id="P50">Most data for individual drug classes that were comparatively well
represented in our cohort were entirely negative but the finding of a signal for
statins which was driven by several class members was entirely novel. Similar to the
more general signal seen on chromosome 2, the chromosome 18 is intergenic with the
closest known gene, cadherin 19 located approx. 300000 bp downstream. Although
functionally such a protein could be of relevance to the liver injury
process,<sup><a href="#R59" rid="R59" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598725208">59</a></sup> any biological
significance seems tenuous. The failure to confirm the signal in additional cases
could be due to the availability of only a small cohort of additional cases which
reflects the rarity of this form of DILI.<sup><a href="#R60" rid="R60" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_598445539">60</a></sup></p><p id="P51" class="p p-last">In conclusion, this study has detected a novel HLA association
(HLA-A*33:01<em>)</em> in cases of DILI due to a number of different
drugs, together with several novel non-HLA signals. Overall sensitivity and
specificity of the A*33:01 allele as a predictor of DILI is low but our findings may
be important for future drug treatment in cases of DILI due to one of the drugs for
which the A*33:01 association is relevant. Follow-up studies are required to further
explore the intergenic signal on chromosome 2, the biologically interesting signal
in <em>LRBA</em> and the rs116561224 signal for statins in larger
cohorts.</p></div><div id="SM" class="tsec sec"><a id="supplementary-material-sec"></a><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="SMtitle">Supplementary Material</h2><!--/article/body/sec/--><div class="sec suppmat" id="SD1"><h4>01</h4><p id="P52"><strong>Figure S1.</strong> Scatterplots representing the first two
principal components of the current study cohort. The homogenous
distribution between cases and controls across the three major European
clusters is shown. In panel (a) cases from phase II are highlighted in red
and the cases from phase I in orange. In panel (b) the cholestatic/mixed
cases are highlighted in red and the hepatocellular cases in blue.</p><p id="P53"><strong>Figure S2.</strong> Regional Manhattan plots for chromosome 2
and 4 in the region of the rs72631567 and rs28521457 signals. (A) Chromosome
2 for the overall cohort, (B) Chromosome 2 for the overall cohort
conditioned on rs72631567. (C) Chromosome 4 for the HC only cohort, (D)
Chromosome 4 for the HC only cohort conditioned on rs28521457.</p><p id="P54"><strong>Figure S3</strong>. QQ plots. (a) for the overall original
analysis (b) after eliminating variants in MHC region. The QQ plot in the
(b) panel highlights the signal on chromosome 2. The inflation factor is
1.05 after correction and 4.65 before correction.</p><p id="P55"><strong>Figure S4</strong>. Scatterplot representing the first two
principal components of the current study cohort. The A*33:01-positive cases
and their injury type are highlighted. A*33:01-positive cases are
homogenously distributed in all the major population clusters.</p><p id="P56"><strong>Figure S5.</strong> MHC Regional Manhattan plots for (a) the
overall cohort (b) the same cohort conditioned on A*33:01 (purple dot) and
(c) the same cohort conditioned on rs114577328 (purple dot).</p><p id="P57"><strong>Figure S6</strong>. QQ plot for (a) Terbinafine cases only, (b)
Cholestatic/Mixed cases only, (c) Hepatocellular cases only.</p><p id="P58"><strong>Figure S7.</strong> MHC Region Manhattan plots for (a) all
cholestatic/mixed cases (b) the same cases conditioned on rs114577328
(purple dot), the top SNP (c) the same cases conditioned on A*33:01 (purple
dot), the top HLA allele</p><p id="P59"><strong>Figure S8.</strong> Manhattan plots for DILI due to (A) Anti-TB
drugs, (B) Fluoroquinolones, (C) NSAIDs, (D) Diclofenac (E)
Nitrofurantoin.</p><p id="P60"><strong>Figure S9.</strong> Regional Manhattan plots for chromosome 18
in the area of the rs116561224 signal for (a) statin-induced DILI cases and
(b) the same cases with conditioning on rs116561224</p><p id="P61"><strong>Table S1</strong>. Causal drugs in the replication cohort.</p><p id="P62"><strong>Table S2</strong>. Genotyping details for the DILI control
cohorts</p><p id="P63"><strong>Table S3.</strong> Causative drugs across the overall DILI
cohort</p><p id="P64"><strong>Table S4</strong>. Effect of the A*33:01, rs72631567 and
rs28521457 signals across populations and recruitment phases</p><p id="P65"><strong>Table S5.</strong> Missing genotypes rate for the most
associated SNPs within case and control groups in the comparisons where SNPs
were significant</p><p id="P66"><strong>Table S6</strong>. Causative drugs across the rs72631567 signal
on chromosome 2</p><p id="P67"><strong>Table S7.</strong> Summary of A*33:01-B*14:02-C*08:02 haplotype
specific analysis across study cohorts</p><p id="P68"><strong>Table S8.</strong> Summary of the validation by direct HLA
typing</p><p id="P69"><strong>Table S9.</strong> The A*33:01 signal across the main six
A*33:01-associated drugs by type of injury</p><p id="P70"><strong>Table S10.</strong> List of all causal drugs where at least one
case carries a A*33:01 allele</p><p id="P71"><strong>Table S11</strong>. The most represented causative drugs across
the rs28521457 signal on chromosome 4</p><p id="P72"><strong>Table S12.</strong> Summary of drug and class comparisons with
more than 40 samples</p><p id="P73"><strong>Table S13.</strong> The most associated variants for each drug
in the class-specific analysis</p><p id="P74"><strong>Table S14.</strong> Causative drugs associated with rs116561224
signal in the statin cohort</p><p id="P75"><strong>Table S15.</strong> Causative drugs associated with the
rs114577328/A*33:01 signal in the additional case set</p><p id="P76"><strong>Table S16.</strong> Causative drugs associated with the
chromosome 2 rs72631567 signal in the additional case set</p><p id="P77"><strong>Table S17.</strong> Causative drugs associated with the
chromosome 4 rs28521457 signal in the additional case set</p><div class="sup-box half_rhythm" id="d36e1550"><a href="/pmc/articles/PMC5367948/bin/NIHMS840066-supplement-01.pdf" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(2.2M, pdf)</sup></div></div></div><div id="S27" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S27title">Acknowledgments</h2><div class="sec"><p id="__p1">Significant case enrollment, sample ascertainment and analytical/data coordinating
support on the DILIGEN, Spanish DILI registry, Eudragene and iDILIC studies was
provided by the International Serious Adverse Events Consortium (iSAEC). We are
extremely grateful to Arthur Holden of iSAEC for his continuing support. We are
grateful to Julia Patch and Julian Arbuckle for technical, study management and
assistance with recruitment on the iDILIC study and to Daniele Cusi (Hypergenes),
Patrik K. Magnusson (Swedish Twin Registry) and Javier Martin (Spanish DNA bank) for
provision of control data. Contributors to sample collection via iDILIC, the Spanish
DILI registry, EUDRAGENE, DILIN, DILIGEN and iSAEC are listed in the <a href="#SD1" rid="SD1" class=" supplementary-material">Appendix</a>.</p><p id="__p2">Funding</p><p id="__p3">The genome-wide association study, HLA genotyping and iDILIC case enrollment and
sample collection was funded by the International Serious Adverse Events Consortium
with (Phase 2) membership support from Abbott, Amgen, Daiichi-Sankyo,
GlaxoSmithKline,Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Takeda, and the
Wellcome Trust. This is a summary of independent research partly (the DILIGEN and
iDILIC sample collection) funded by the National Institute for Health Research
(NIHR) Nottingham Digestive Diseases Biomedical Research Unit at the Nottingham
University Hospitals NHS Trust and University of Nottingham. The views expressed are
those of the author(s) and not necessarily those of the NHS, the NIHR or the
Department of Health. The DILIN (<a href="https://dilin.dcri.duke.edu/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">https://dilin.dcri.duke.edu/</a>) is supported by the National Institute
of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health
(NIH) as a Cooperative Agreement (U01s) under grants: U01-<a id="__tag_805646798" class="tag_hotlink" href="/nuccore/DK065176" ref="/nuccore/DK065176"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"DK065176","term_id":"187462308","term_text":"DK065176"}}</span>DK065176</a> (Duke),
U01-<a id="__tag_805646801" class="tag_hotlink" href="/nuccore/DK065201" ref="/nuccore/DK065201"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"DK065201","term_id":"187464418","term_text":"DK065201"}}</span>DK065201</a> (UNC), U01-<a id="__tag_805646802" class="tag_hotlink" href="/nuccore/DK065184" ref="/nuccore/DK065184"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"DK065184","term_id":"187462316","term_text":"DK065184"}}</span>DK065184</a> (Michigan), U01-<a id="__tag_805646800" class="tag_hotlink" href="/nuccore/DK065211" ref="/nuccore/DK065211"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"DK065211","term_id":"187464428","term_text":"DK065211"}}</span>DK065211</a> (Indiana), U01DK065193
(UConn), U01-<a id="__tag_805646795" class="tag_hotlink" href="/nuccore/DK065238" ref="/nuccore/DK065238"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"DK065238","term_id":"187465029","term_text":"DK065238"}}</span>DK065238</a> (UCSF/CPMC), U01-<a id="__tag_805646797" class="tag_hotlink" href="/nuccore/DK083023" ref="/nuccore/DK083023"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"DK083023","term_id":"187396314","term_text":"DK083023"}}</span>DK083023</a> (UTSW), U01-<a id="__tag_805646796" class="tag_hotlink" href="/nuccore/DK083027" ref="/nuccore/DK083027"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"DK083027","term_id":"187396318","term_text":"DK083027"}}</span>DK083027</a> (TJH/UPenn),
U01-<a id="__tag_805646803" class="tag_hotlink" href="/nuccore/DK082992" ref="/nuccore/DK082992"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"DK082992","term_id":"187394197","term_text":"DK082992"}}</span>DK082992</a> (Mayo), U01-<a id="__tag_805646794" class="tag_hotlink" href="/nuccore/DK083020" ref="/nuccore/DK083020"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"DK083020","term_id":"187394281","term_text":"DK083020"}}</span>DK083020</a> (USC), U01-<a id="__tag_805646799" class="tag_hotlink" href="/nuccore/DK100928" ref="/nuccore/DK100928"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"DK100928","term_id":"187499724","term_text":"DK100928"}}</span>DK100928</a> (Icahn). Additional funding is
provided by CTSA grants UL1 RR025761 (Indiana), UL1 TR001111 (UNC), and UL1 UL1
RR024986 (UMich). The EUDRAGENE collaboration received support from the EC 5th
Framework program (QLRI-CT-2002-02757). The Spanish DILI Registry is partly funded
by the Spanish Medicine Agency, Fondo Europeo de Desarrollo Regional - FEDER
(P10-CTS-6470, FIS PI12/00378). CIBERehd is funded by Instituto de Salud Carlos III.
The Swedish case collection (SWEDEGENE) has received support from the Swedish
Medical Products Agency, the Swedish Society of Medicine (2008-21619), Swedish
Research Council (Medicine 521-2011-2440), and Swedish Heart and Lung Foundation
(20120557). MM was supported by the National Institute for Health Research (NIHR)
Biomedical Research Centre at Guy's and St Thomas' NHS Foundation
Trust and King's College London. LI was supported by Instituto de Salud
Carlos III (EC08/00250). MA was supported by CONICYT PIA/Basal PFB12.</p><p id="__p4">The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.</p></div></div><div id="idm139620996328832" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm139620996328832title">Abbreviations</h2><div class="bk-sec"><div><table class="default-table glossary"><tbody><tr><td>DILI</td><td>drug-induced liver injury</td></tr><tr><td>GWAS</td><td>genome wide association study</td></tr><tr><td>OR</td><td>Odd Ratio</td></tr><tr><td>RUCAM</td><td>Roussel Uclaf Causality Assessment Method</td></tr><tr><td>AF</td><td>Allele Frequency</td></tr><tr><td>HC</td><td>Hepatocellular</td></tr><tr><td>CM</td><td>Cholestatic-Mixed</td></tr><tr><td>eQTL</td><td>Expression quantitative trait loci</td></tr><tr><td>MHC</td><td>Major Histocompatibility Complex</td></tr><tr><td>MAF</td><td>Minor allele frequency</td></tr><tr><td>LD</td><td>Linkage Disequilibrium</td></tr><tr><td>HLA</td><td>Human leukocyte antigen</td></tr><tr><td>SNP</td><td>Single Nucleotide Polymorphism</td></tr></tbody></table></div></div></div><div id="idm139620997605344" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm139620997605344title">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="FN3"></p><p id="P78" class="p p-first-last"><strong>Conflicts of interest:</strong> The authors disclose the following:
Dr Nelson is an employee of GlaxoSmithKline. Drs Chalasani, Fontana, and Watkins
report consulting agreements and research grants with several pharmaceutical
companies but none represent as potential conflicts for this paper. The DILIN
causality committee considers potential conflicts while assigning cases for
adjudication to individual investigators. The remaining authors disclose no
conflicts.</p><p></p><p class="fn sec" id="FN4"></p><p id="P79" class="p p-first">Author contribution:</p><p id="P80" class="p">Study concept and design: Guruprasad P. Aithal, Paul B. Watkins, Matthew
R. Nelson, Thomas J. Urban and Ann K. Daly</p><p id="P81" class="p">Case recruitment and data acquisition: Guruprasad P. Aithal, Marco
Arrese, Einar Bjornsson, Raul J. Andrade, Pär Hallberg, Mia Wadelius, M.
Isabel Lucena, Camilla Stephens, Sally A. Coulthard, Anke H. Maitland-van der
Zee, Jennifer H. Martin, Ingolf Cascorbi, Christopher P. Day, John F. Dillon,
Tarja Laitinen, Dominique Larrey, Mariam Molokhia, Gerd A. Kullak-Ublick, Luisa
Ibáñez, Munir Pirmohamed, Shengying Qin, Fernando Bessone, Marco
Arrese, Elizabeth Powell, Anita Conforti, Emmanuelle Bondon-Guitton, Alfonso
Carvajal, Robert J. Fontana, Nelia Hernández, Jane I. Grove, Jose
Serrano, Andrew Stolz, Victor Navarro, Herbert L. Bonkovsky, Huiman X. Barnhart,
Naga Chalasani, Paul B. Watkins and Ann K. Daly</p><p id="P82" class="p">Case adjudication: Guruprasad P. Aithal, Einar Bjornsson and Raul J.
Andrade for iDILIC; Robert J. Fontana, Paul H. Hayashi, Andrew Stolz, Jose
Serrano and Paul B. Watkins for DILIN</p><p id="P83" class="p">Sample preparation and laboratory analysis: Camilla Stephens, Sally A.
Coulthard Mark J. Daly and Jane Grove</p><p id="P84" class="p">Data analysis and interpretation: Paola Nicoletti, Ashley Sawle, Yufeng
Shen, Aris Floratos, Guruprasad P. Aithal, Mark J. Daly, Elizabeth T. Cirulli,
Thomas J. Urban, Matthew R. Nelson, Paul B. Watkins and Ann K. Daly</p><p id="P85" class="p">Writing the manuscript: Paola Nicoletti, Guruprasad P. Aithal, Thomas J.
Urban, Paul B. Watkins and Ann K. Daly</p><p id="P86" class="p">Critical revision of manuscript for important intellectual content
particularly in statistical analysis: Matthew R. Nelson and Yufeng Shen</p><p id="P87" class="p p-last">Drs Nicoletti, Aithal, Urban and Daly contributed equally to this
manuscript.</p><p></p><p class="fn sec" id="FN5"></p><p id="P88" class="p p-first-last"><strong>Publisher's Disclaimer: </strong>This is a PDF file of an unedited
manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will
undergo copyediting, typesetting, and review of the resulting proof before it is
published in its final citable form. Please note that during the production
process errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.</p><p></p></div></div><div id="idm139620984766304" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm139620984766304title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="R1">1. <span class="element-citation">Stevens JL, Baker TK. The future of drug safety testing: expanding the view and
narrowing the focus. <span><span class="ref-journal">Drug Discov Today. </span>2009;<span class="ref-vol">14</span>:162–7.</span> [<a href="/pubmed/19100337" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Drug+Discov+Today&amp;title=The+future+of+drug+safety+testing:+expanding+the+view+and
narrowing+the+focus&amp;author=JL+Stevens&amp;author=TK+Baker&amp;volume=14&amp;publication_year=2009&amp;pages=162-7&amp;pmid=19100337&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R2">2. <span class="element-citation">Gulmez SE, Larrey D, Pageaux GP, et al.  Transplantation for acute liver failure in patients exposed to
NSAIDs or paracetamol (acetaminophen): the multinational case-population
SALT study. <span><span class="ref-journal">Drug Saf. </span>2013;<span class="ref-vol">36</span>:135–44.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3568201/">PMC free article</a>]</span> [<a href="/pubmed/23325533" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Drug+Saf&amp;title=Transplantation+for+acute+liver+failure+in+patients+exposed+to
NSAIDs+or+paracetamol+(acetaminophen):+the+multinational+case-population
SALT+study&amp;author=SE+Gulmez&amp;author=D+Larrey&amp;author=GP+Pageaux&amp;volume=36&amp;publication_year=2013&amp;pages=135-44&amp;pmid=23325533&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R3">3. <span class="element-citation">Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a U.S. multicenter,
prospective study. <span><span class="ref-journal">Hepatology. </span>2010;<span class="ref-vol">52</span>:2065–76.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3992250/">PMC free article</a>]</span> [<a href="/pubmed/20949552" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=Drug-induced+acute+liver+failure:+results+of+a+U.S.+multicenter,
prospective+study&amp;author=A+Reuben&amp;author=DG+Koch&amp;author=WM+Lee&amp;volume=52&amp;publication_year=2010&amp;pages=2065-76&amp;pmid=20949552&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R4">4. <span class="element-citation">Bjornsson ES, Gunnarsson BI, Grondal G, et al.  Risk of drug-induced liver injury from tumor necrosis factor
antagonists. <span><span class="ref-journal">Clin Gastroenterol Hepatol. </span>2015;<span class="ref-vol">13</span>:602–8.</span> [<a href="/pubmed/25131534" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Gastroenterol+Hepatol&amp;title=Risk+of+drug-induced+liver+injury+from+tumor+necrosis+factor
antagonists&amp;author=ES+Bjornsson&amp;author=BI+Gunnarsson&amp;author=G+Grondal&amp;volume=13&amp;publication_year=2015&amp;pages=602-8&amp;pmid=25131534&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R5">5. <span class="element-citation">Bjornsson ES, Bergmann OM, Bjornsson HK, et al.  Incidence, presentation, and outcomes in patients with
drug-induced liver injury in the general population of
Iceland. <span><span class="ref-journal">Gastroenterology. </span>2013;<span class="ref-vol">144</span>:1419–25. 1425, e1–3.</span> quiz e19-20. [<a href="/pubmed/23419359" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=Incidence,+presentation,+and+outcomes+in+patients+with
drug-induced+liver+injury+in+the+general+population+of
Iceland&amp;author=ES+Bjornsson&amp;author=OM+Bergmann&amp;author=HK+Bjornsson&amp;volume=144&amp;publication_year=2013&amp;pages=1419-25&amp;pmid=23419359&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R6">6. <span class="element-citation">Urban TJ, Daly AK, Aithal GR. Genetic Basis of Drug-Induced Liver Injury: Present and
Future. <span><span class="ref-journal">Semin Liver Dis. </span>2014;<span class="ref-vol">34</span>:123–133.</span> [<a href="/pubmed/24879978" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Semin+Liver+Dis&amp;title=Genetic+Basis+of+Drug-Induced+Liver+Injury:+Present+and
Future&amp;author=TJ+Urban&amp;author=AK+Daly&amp;author=GR+Aithal&amp;volume=34&amp;publication_year=2014&amp;pages=123-133&amp;pmid=24879978&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R7">7. <span class="element-citation">Kindmark A, Jawaid A, Harbron CG, et al.  Genome-wide pharmacogenetic investigation of a hepatic adverse
event without clinical signs of immunopathology suggests an underlying
immune pathogenesis. <span><span class="ref-journal">Pharmacogenomics J. </span>2008;<span class="ref-vol">8</span>:186–95.</span> [<a href="/pubmed/17505501" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacogenomics+J&amp;title=Genome-wide+pharmacogenetic+investigation+of+a+hepatic+adverse
event+without+clinical+signs+of+immunopathology+suggests+an+underlying
immune+pathogenesis&amp;author=A+Kindmark&amp;author=A+Jawaid&amp;author=CG+Harbron&amp;volume=8&amp;publication_year=2008&amp;pages=186-95&amp;pmid=17505501&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R8">8. <span class="element-citation">Daly AK, Donaldson PT, Bhatnagar P, et al.  HLA-B*5701 genotype is a major determinant of drug-induced liver
injury due to flucloxacillin. <span><span class="ref-journal">Nat Genet. </span>2009;<span class="ref-vol">41</span>:816–819.</span> [<a href="/pubmed/19483685" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Genet&amp;title=HLA-B*5701+genotype+is+a+major+determinant+of+drug-induced+liver
injury+due+to+flucloxacillin&amp;author=AK+Daly&amp;author=PT+Donaldson&amp;author=P+Bhatnagar&amp;volume=41&amp;publication_year=2009&amp;pages=816-819&amp;pmid=19483685&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R9">9. <span class="element-citation">Singer JB, Lewitzky S, Leroy E, et al.  A genome-wide study identifies HLA alleles associated with
lumiracoxib-related liver injury. <span><span class="ref-journal">Nat Genet. </span>2010;<span class="ref-vol">42</span>:711–4.</span> [<a href="/pubmed/20639878" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Genet&amp;title=A+genome-wide+study+identifies+HLA+alleles+associated+with
lumiracoxib-related+liver+injury&amp;author=JB+Singer&amp;author=S+Lewitzky&amp;author=E+Leroy&amp;volume=42&amp;publication_year=2010&amp;pages=711-4&amp;pmid=20639878&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R10">10. <span class="element-citation">Lucena MI, Molokhia M, Shen Y, et al.  Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury Is
Influenced by Multiple HLA Class I and II Alleles. <span><span class="ref-journal">Gastroenterology. </span>2011;<span class="ref-vol">141</span>:338–47.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3129430/">PMC free article</a>]</span> [<a href="/pubmed/21570397" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=Susceptibility+to+Amoxicillin-Clavulanate-Induced+Liver+Injury+Is
Influenced+by+Multiple+HLA+Class+I+and+II+Alleles&amp;author=MI+Lucena&amp;author=M+Molokhia&amp;author=Y+Shen&amp;volume=141&amp;publication_year=2011&amp;pages=338-47&amp;pmid=21570397&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R11">11. <span class="element-citation">Spraggs CF, Budde LR, Briley LP, et al.  HLA-DQA1*02:01 Is a Major Risk Factor for Lapatinib-Induced
Hepatotoxicity in Women With Advanced Breast Cancer. <span><span class="ref-journal">J Clin Oncol. </span>2011;<span class="ref-vol">29</span>:667–73.</span> [<a href="/pubmed/21245432" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=HLA-DQA1*02:01+Is+a+Major+Risk+Factor+for+Lapatinib-Induced
Hepatotoxicity+in+Women+With+Advanced+Breast+Cancer&amp;author=CF+Spraggs&amp;author=LR+Budde&amp;author=LP+Briley&amp;volume=29&amp;publication_year=2011&amp;pages=667-73&amp;pmid=21245432&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R12">12. <span class="element-citation">Urban TJ, Shen Y, Stolz A, et al.  Limited contribution of common genetic variants to risk for liver
injury due to a variety of drugs. <span><span class="ref-journal">Pharmacogenet Genomics. </span>2012;<span class="ref-vol">22</span>:784–95.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3636716/">PMC free article</a>]</span> [<a href="/pubmed/22968431" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacogenet+Genomics&amp;title=Limited+contribution+of+common+genetic+variants+to+risk+for+liver
injury+due+to+a+variety+of+drugs&amp;author=TJ+Urban&amp;author=Y+Shen&amp;author=A+Stolz&amp;volume=22&amp;publication_year=2012&amp;pages=784-95&amp;pmid=22968431&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R13">13. <span class="element-citation">Bjornsson ES. Drug-induced liver injury: an overview over the most critical
compounds. <span><span class="ref-journal">Arch Toxicol. </span>2015;<span class="ref-vol">89</span>:327–34.</span> [<a href="/pubmed/25618544" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Arch+Toxicol&amp;title=Drug-induced+liver+injury:+an+overview+over+the+most+critical
compounds&amp;author=ES+Bjornsson&amp;volume=89&amp;publication_year=2015&amp;pages=327-34&amp;pmid=25618544&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R14">14. <span class="element-citation">Nicoletti P, Werk AN, Sawle A, et al.  HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for
flupirtine-induced liver injury. <span><span class="ref-journal">Pharmacogenet Genomics. </span>2016;<span class="ref-vol">26</span>:218–24.</span> [<a href="/pubmed/26959717" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacogenet+Genomics&amp;title=HLA-DRB1*16:+01-DQB1*05:+02+is+a+novel+genetic+risk+factor+for
flupirtine-induced+liver+injury&amp;author=P+Nicoletti&amp;author=AN+Werk&amp;author=A+Sawle&amp;volume=26&amp;publication_year=2016&amp;pages=218-24&amp;pmid=26959717&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R15">15. <span class="element-citation">Aithal GP, Watkins PB, Andrade RJ, et al.  Case Definition and Phenotype Standardization in Drug-Induced
Liver Injury. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2011;<span class="ref-vol">89</span>:806–815.</span> [<a href="/pubmed/21544079" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Pharmacol+Ther&amp;title=Case+Definition+and+Phenotype+Standardization+in+Drug-Induced
Liver+Injury&amp;author=GP+Aithal&amp;author=PB+Watkins&amp;author=RJ+Andrade&amp;volume=89&amp;publication_year=2011&amp;pages=806-815&amp;pmid=21544079&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R16">16. <span class="element-citation">Fontana RJ, Watkins PB, Bonkovsky HL, et al.  Drug-Induced Liver Injury Network (DILIN) prospective study:
rationale, design and conduct. <span><span class="ref-journal">Drug Saf. </span>2009;<span class="ref-vol">32</span>:55–68.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3637941/">PMC free article</a>]</span> [<a href="/pubmed/19132805" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Drug+Saf&amp;title=Drug-Induced+Liver+Injury+Network+(DILIN)+prospective+study:
rationale,+design+and+conduct&amp;author=RJ+Fontana&amp;author=PB+Watkins&amp;author=HL+Bonkovsky&amp;volume=32&amp;publication_year=2009&amp;pages=55-68&amp;pmid=19132805&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R17">17. <span class="element-citation">Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs--II. An
original model for validation of drug causality assessment methods: case
reports with positive rechallenge. <span><span class="ref-journal">J Clin Epidemiol. </span>1993;<span class="ref-vol">46</span>:1331–6.</span> [<a href="/pubmed/8229111" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Epidemiol&amp;title=Causality+assessment+of+adverse+reactions+to+drugs--II.+An
original+model+for+validation+of+drug+causality+assessment+methods:+case
reports+with+positive+rechallenge&amp;author=C+Benichou&amp;author=G+Danan&amp;author=A+Flahault&amp;volume=46&amp;publication_year=1993&amp;pages=1331-6&amp;pmid=8229111&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R18">18. <span class="element-citation">Nelson MR, Bryc K, King KS, et al.  The Population Reference Sample, POPRES: a resource for
population, disease, and pharmacological genetics research. <span><span class="ref-journal">Am J Hum Genet. </span>2008;<span class="ref-vol">83</span>:347–58.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2556436/">PMC free article</a>]</span> [<a href="/pubmed/18760391" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Hum+Genet&amp;title=The+Population+Reference+Sample,+POPRES:+a+resource+for
population,+disease,+and+pharmacological+genetics+research&amp;author=MR+Nelson&amp;author=K+Bryc&amp;author=KS+King&amp;volume=83&amp;publication_year=2008&amp;pages=347-58&amp;pmid=18760391&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R19">19. <span class="element-citation">Shen Y, Nicoletti P, Floratos A, et al.  Genome-wide association study of serious blistering skin rash
caused by drugs. <span><span class="ref-journal">Pharmacogenomics J. </span>2012;<span class="ref-vol">12</span>:96–104.</span> [<a href="/pubmed/21221126" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacogenomics+J&amp;title=Genome-wide+association+study+of+serious+blistering+skin+rash
caused+by+drugs&amp;author=Y+Shen&amp;author=P+Nicoletti&amp;author=A+Floratos&amp;volume=12&amp;publication_year=2012&amp;pages=96-104&amp;pmid=21221126&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R20">20. <span class="element-citation">Tryka KA, Hao L, Sturcke A, et al.  NCBI's Database of Genotypes and Phenotypes:
dbGaP. <span><span class="ref-journal">Nucleic Acids Res. </span>2014;<span class="ref-vol">42</span>:D975–9.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3965052/">PMC free article</a>]</span> [<a href="/pubmed/24297256" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nucleic+Acids+Res&amp;title=NCBI's+Database+of+Genotypes+and+Phenotypes:
dbGaP&amp;author=KA+Tryka&amp;author=L+Hao&amp;author=A+Sturcke&amp;volume=42&amp;publication_year=2014&amp;pages=D975-9&amp;pmid=24297256&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R21">21. <span class="element-citation">Zheng X, Shen J, Cox C, et al.  HIBAG--HLA genotype imputation with attribute
bagging. <span><span class="ref-journal">Pharmacogenomics J. </span>2014;<span class="ref-vol">14</span>:192–200.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3772955/">PMC free article</a>]</span> [<a href="/pubmed/23712092" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacogenomics+J&amp;title=HIBAG--HLA+genotype+imputation+with+attribute
bagging&amp;author=X+Zheng&amp;author=J+Shen&amp;author=C+Cox&amp;volume=14&amp;publication_year=2014&amp;pages=192-200&amp;pmid=23712092&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R22">22. <span class="element-citation">Price AL, Patterson NJ, Plenge RM, et al.  Principal components analysis corrects for stratification in
genome-wide association studies. <span><span class="ref-journal">Nat Genet. </span>2006;<span class="ref-vol">38</span>:904–909.</span> [<a href="/pubmed/16862161" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Genet&amp;title=Principal+components+analysis+corrects+for+stratification+in
genome-wide+association+studies&amp;author=AL+Price&amp;author=NJ+Patterson&amp;author=RM+Plenge&amp;volume=38&amp;publication_year=2006&amp;pages=904-909&amp;pmid=16862161&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R23">23. <span class="element-citation">Purcell S, Neale B, Todd-Brown K, et al.  PLINK: a tool set for whole-genome association and
population-based linkage analyses. <span><span class="ref-journal">Am J Hum Genet. </span>2007;<span class="ref-vol">81</span>:559–75.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1950838/">PMC free article</a>]</span> [<a href="/pubmed/17701901" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Hum+Genet&amp;title=PLINK:+a+tool+set+for+whole-genome+association+and
population-based+linkage+analyses&amp;author=S+Purcell&amp;author=B+Neale&amp;author=K+Todd-Brown&amp;volume=81&amp;publication_year=2007&amp;pages=559-75&amp;pmid=17701901&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R24">24. <span class="element-citation">McCarthy MI. Casting a wider net for diabetes susceptibility
genes. <span><span class="ref-journal">Nat Genet. </span>2008;<span class="ref-vol">40</span>:1039–40.</span> [<a href="/pubmed/19165915" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Genet&amp;title=Casting+a+wider+net+for+diabetes+susceptibility
genes&amp;author=MI+McCarthy&amp;volume=40&amp;publication_year=2008&amp;pages=1039-40&amp;pmid=19165915&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R25">25. <span class="element-citation"><span><span class="ref-journal">The R Project for Statistical Computing. </span></span>  <a href="http://wwwr-projectorg" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">http://wwwr-projectorg</a>.</span></div><div class="ref-cit-blk half_rhythm" id="R26">26. <span class="element-citation">Pruim RJ, Welch RP, Sanna S, et al.  LocusZoom: regional visualization of genome-wide association scan
results. <span><span class="ref-journal">Bioinformatics. </span>2010;<span class="ref-vol">26</span>:2336–7.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2935401/">PMC free article</a>]</span> [<a href="/pubmed/20634204" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Bioinformatics&amp;title=LocusZoom:+regional+visualization+of+genome-wide+association+scan
results&amp;author=RJ+Pruim&amp;author=RP+Welch&amp;author=S+Sanna&amp;volume=26&amp;publication_year=2010&amp;pages=2336-7&amp;pmid=20634204&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R27">27. <span class="element-citation">Haimila K, Perasaari J, Linjama T, et al.  HLA antigen, allele and haplotype frequencies and their use in
virtual panel reactive antigen calculations in the Finnish
population. <span><span class="ref-journal">Tissue Antigens. </span>2013;<span class="ref-vol">81</span>:35–43.</span> [<a href="/pubmed/23216287" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Tissue+Antigens&amp;title=HLA+antigen,+allele+and+haplotype+frequencies+and+their+use+in
virtual+panel+reactive+antigen+calculations+in+the+Finnish
population&amp;author=K+Haimila&amp;author=J+Perasaari&amp;author=T+Linjama&amp;volume=81&amp;publication_year=2013&amp;pages=35-43&amp;pmid=23216287&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R28">28. <span class="element-citation">Ostrov DA, Grant BJ, Pompeu YA, et al.  Drug hypersensitivity caused by alteration of the MHC-presented
self-peptide repertoire. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2012;<span class="ref-vol">109</span>:9959–64.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3382472/">PMC free article</a>]</span> [<a href="/pubmed/22645359" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U+S+A&amp;title=Drug+hypersensitivity+caused+by+alteration+of+the+MHC-presented
self-peptide+repertoire&amp;author=DA+Ostrov&amp;author=BJ+Grant&amp;author=YA+Pompeu&amp;volume=109&amp;publication_year=2012&amp;pages=9959-64&amp;pmid=22645359&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R29">29. <span class="element-citation">Iverson SL, Uetrecht JP. Identification of a reactive metabolite of terbinafine: insights
into terbinafine-induced hepatotoxicity. <span><span class="ref-journal">Chem Res Toxicol. </span>2001;<span class="ref-vol">14</span>:175–81.</span> [<a href="/pubmed/11258966" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Chem+Res+Toxicol&amp;title=Identification+of+a+reactive+metabolite+of+terbinafine:+insights
into+terbinafine-induced+hepatotoxicity&amp;author=SL+Iverson&amp;author=JP+Uetrecht&amp;volume=14&amp;publication_year=2001&amp;pages=175-81&amp;pmid=11258966&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R30">30. <span class="element-citation">Mizuno K, Fukami T, Toyoda Y, et al.  Terbinafine stimulates the proinflammatory responses in human
monocytic THP-1 cells through an ERK signaling pathway. <span><span class="ref-journal">Life Sci. </span>2010;<span class="ref-vol">87</span>:537–44.</span> [<a href="/pubmed/20816994" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Life+Sci&amp;title=Terbinafine+stimulates+the+proinflammatory+responses+in+human
monocytic+THP-1+cells+through+an+ERK+signaling+pathway&amp;author=K+Mizuno&amp;author=T+Fukami&amp;author=Y+Toyoda&amp;volume=87&amp;publication_year=2010&amp;pages=537-44&amp;pmid=20816994&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R31">31. <span class="element-citation">Vickers AE, Sinclair JR, Zollinger M, et al.  Multiple cytochrome P-450s involved in the metabolism of
terbinafine suggest a limited potential for drug-drug
interactions. <span><span class="ref-journal">Drug Metabolism and Disposition. </span>1999;<span class="ref-vol">27</span>:1029–38.</span> [<a href="/pubmed/10460803" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Drug+Metabolism+and+Disposition&amp;title=Multiple+cytochrome+P-450s+involved+in+the+metabolism+of
terbinafine+suggest+a+limited+potential+for+drug-drug
interactions&amp;author=AE+Vickers&amp;author=JR+Sinclair&amp;author=M+Zollinger&amp;volume=27&amp;publication_year=1999&amp;pages=1029-38&amp;pmid=10460803&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R32">32. <span class="element-citation">Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives
(fibrates) <span><span class="ref-journal">Clin Pharmacokinet. </span>1998;<span class="ref-vol">34</span>:155–62.</span> [<a href="/pubmed/9515185" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Pharmacokinet&amp;title=Clinical+pharmacokinetics+of+fibric+acid+derivatives
(fibrates)&amp;author=DB+Miller&amp;author=JD+Spence&amp;volume=34&amp;publication_year=1998&amp;pages=155-62&amp;pmid=9515185&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R33">33. <span class="element-citation">Lucena MI, Andrade RJ, Vicioso L, et al.  Prolonged cholestasis after raloxifene and fenofibrate
interaction: A case report. <span><span class="ref-journal">World J Gastroenterol. </span>2006;<span class="ref-vol">12</span>:5244–6.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4088030/">PMC free article</a>]</span> [<a href="/pubmed/16937543" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=World+J+Gastroenterol&amp;title=Prolonged+cholestasis+after+raloxifene+and+fenofibrate
interaction:+A+case+report&amp;author=MI+Lucena&amp;author=RJ+Andrade&amp;author=L+Vicioso&amp;volume=12&amp;publication_year=2006&amp;pages=5244-6&amp;pmid=16937543&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R34">34. <span class="element-citation">Hajdu D, Aiglova K, Vinklerova I, et al.  Acute cholestatic hepatitis induced by
fenofibrate. <span><span class="ref-journal">J Clin Pharm Ther. </span>2009;<span class="ref-vol">34</span>:599–602.</span> [<a href="/pubmed/19744016" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Pharm+Ther&amp;title=Acute+cholestatic+hepatitis+induced+by
fenofibrate&amp;author=D+Hajdu&amp;author=K+Aiglova&amp;author=I+Vinklerova&amp;volume=34&amp;publication_year=2009&amp;pages=599-602&amp;pmid=19744016&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R35">35. <span class="element-citation">Skurnik YD, Tcherniak A, Edlan K, et al.  Ticlopidine-induced cholestatic hepatitis. <span><span class="ref-journal">Ann Pharmacother. </span>2003;<span class="ref-vol">37</span>:371–5.</span> [<a href="/pubmed/12639165" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ann+Pharmacother&amp;title=Ticlopidine-induced+cholestatic+hepatitis&amp;author=YD+Skurnik&amp;author=A+Tcherniak&amp;author=K+Edlan&amp;volume=37&amp;publication_year=2003&amp;pages=371-5&amp;pmid=12639165&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R36">36. <span class="element-citation">Pizarro AE, Andrade RJ, Garcia-Cortes M, et al.  [Acute hepatitis due to ticlopidine. A report of 12 cases and
review of the literature] <span><span class="ref-journal">Rev Neurol. </span>2001;<span class="ref-vol">33</span>:1014–20.</span> [<a href="/pubmed/11785026" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Rev+Neurol&amp;title=[Acute+hepatitis+due+to+ticlopidine.+A+report+of+12+cases+and
review+of+the+literature]&amp;author=AE+Pizarro&amp;author=RJ+Andrade&amp;author=M+Garcia-Cortes&amp;volume=33&amp;publication_year=2001&amp;pages=1014-20&amp;pmid=11785026&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R37">37. <span class="element-citation">Kim MJ, Jeong ES, Park JS, et al.  Multiple cytochrome P450 isoforms are involved in the generation
of a pharmacologically active thiol metabolite, whereas paraoxonase 1 and
carboxylesterase 1 catalyze the formation of a thiol metabolite isomer from
ticlopidine. <span><span class="ref-journal">Drug Metabolism and Disposition. </span>2014;<span class="ref-vol">42</span>:141–52.</span> [<a href="/pubmed/24170778" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Drug+Metabolism+and+Disposition&amp;title=Multiple+cytochrome+P450+isoforms+are+involved+in+the+generation
of+a+pharmacologically+active+thiol+metabolite,+whereas+paraoxonase+1+and
carboxylesterase+1+catalyze+the+formation+of+a+thiol+metabolite+isomer+from
ticlopidine&amp;author=MJ+Kim&amp;author=ES+Jeong&amp;author=JS+Park&amp;volume=42&amp;publication_year=2014&amp;pages=141-52&amp;pmid=24170778&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R38">38. <span class="element-citation">Yoshikado T, Takada T, Yamamoto H, et al.  Ticlopidine, a cholestatic liver injury-inducible drug, causes
dysfunction of bile formation via diminished biliary secretion of
phospholipids: involvement of biliary-excreted glutathione-conjugated
ticlopidine metabolites. <span><span class="ref-journal">Mol Pharmacol. </span>2013;<span class="ref-vol">83</span>:552–62.</span> [<a href="/pubmed/23220748" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Pharmacol&amp;title=Ticlopidine,+a+cholestatic+liver+injury-inducible+drug,+causes
dysfunction+of+bile+formation+via+diminished+biliary+secretion+of
phospholipids:+involvement+of+biliary-excreted+glutathione-conjugated
ticlopidine+metabolites&amp;author=T+Yoshikado&amp;author=T+Takada&amp;author=H+Yamamoto&amp;volume=83&amp;publication_year=2013&amp;pages=552-62&amp;pmid=23220748&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R39">39. <span class="element-citation">Hirata K, Takagi H, Yamamoto M, et al.  Ticlopidine-induced hepatotoxicity is associated with specific
human leukocyte antigen genomic subtypes in Japanese patients: a preliminary
case-control study. <span><span class="ref-journal">Pharmacogenomics J. </span>2008;<span class="ref-vol">8</span>:29–33.</span> [<a href="/pubmed/17339877" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacogenomics+J&amp;title=Ticlopidine-induced+hepatotoxicity+is+associated+with+specific
human+leukocyte+antigen+genomic+subtypes+in+Japanese+patients:+a+preliminary
case-control+study&amp;author=K+Hirata&amp;author=H+Takagi&amp;author=M+Yamamoto&amp;volume=8&amp;publication_year=2008&amp;pages=29-33&amp;pmid=17339877&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R40">40. <span class="element-citation">Ariyoshi N, Iga Y, Hirata K, et al.  Enhanced susceptibility of HLA-mediated ticlopidine-induced
idiosyncratic hepatotoxicity by CYP2B6 polymorphism in
Japanese. <span><span class="ref-journal">Drug Metab Pharmacokinet. </span>2010;<span class="ref-vol">25</span>:298–306.</span> [<a href="/pubmed/20610889" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Drug+Metab+Pharmacokinet&amp;title=Enhanced+susceptibility+of+HLA-mediated+ticlopidine-induced
idiosyncratic+hepatotoxicity+by+CYP2B6+polymorphism+in
Japanese&amp;author=N+Ariyoshi&amp;author=Y+Iga&amp;author=K+Hirata&amp;volume=25&amp;publication_year=2010&amp;pages=298-306&amp;pmid=20610889&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R41">41. <span class="element-citation">Raccor BS, Claessens AJ, Dinh JC, et al.  Potential contribution of cytochrome P450 2B6 to hepatic
4-hydroxycyclophosphamide formation in vitro and in vivo. <span><span class="ref-journal">Drug Metab Dispos. </span>2012;<span class="ref-vol">40</span>:54–63.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3250049/">PMC free article</a>]</span> [<a href="/pubmed/21976622" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Drug+Metab+Dispos&amp;title=Potential+contribution+of+cytochrome+P450+2B6+to+hepatic
4-hydroxycyclophosphamide+formation+in+vitro+and+in+vivo&amp;author=BS+Raccor&amp;author=AJ+Claessens&amp;author=JC+Dinh&amp;volume=40&amp;publication_year=2012&amp;pages=54-63&amp;pmid=21976622&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R42">42. <span class="element-citation">Fartoux-Heymann L, Hezode C, Zafrani ES, et al.  Acute fatal hepatitis related to sertraline. <span><span class="ref-journal">J Hepatol. </span>2001;<span class="ref-vol">35</span>:683–4.</span> [<a href="/pubmed/11690719" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Hepatol&amp;title=Acute+fatal+hepatitis+related+to+sertraline&amp;author=L+Fartoux-Heymann&amp;author=C+Hezode&amp;author=ES+Zafrani&amp;volume=35&amp;publication_year=2001&amp;pages=683-4&amp;pmid=11690719&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R43">43. <span class="element-citation">Tabak F, Gunduz F, Tahan V, et al.  Sertraline hepatotoxicity: report of a case and review of the
literature. <span><span class="ref-journal">Dig Dis Sci. </span>2009;<span class="ref-vol">54</span>:1589–91.</span> [<a href="/pubmed/18958618" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Dig+Dis+Sci&amp;title=Sertraline+hepatotoxicity:+report+of+a+case+and+review+of+the
literature&amp;author=F+Tabak&amp;author=F+Gunduz&amp;author=V+Tahan&amp;volume=54&amp;publication_year=2009&amp;pages=1589-91&amp;pmid=18958618&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R44">44. <span class="element-citation">Suen CF, Boyapati R, Simpson I, et al.  Acute liver injury secondary to sertraline. <span><span class="ref-journal">BMJ Case Rep. </span>2013;<span class="ref-vol">2013</span></span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3794285/">PMC free article</a>]</span> [<a href="/pubmed/24072839" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=BMJ+Case+Rep&amp;title=Acute+liver+injury+secondary+to+sertraline&amp;author=CF+Suen&amp;author=R+Boyapati&amp;author=I+Simpson&amp;volume=2013&amp;publication_year=2013&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R45">45. <span class="element-citation">Chen S, Xuan J, Couch L, et al.  Sertraline induces endoplasmic reticulum stress in hepatic
cells. <span><span class="ref-journal">Toxicology. </span>2014;<span class="ref-vol">322</span>:78–88.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5736318/">PMC free article</a>]</span> [<a href="/pubmed/24865413" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Toxicology&amp;title=Sertraline+induces+endoplasmic+reticulum+stress+in+hepatic
cells&amp;author=S+Chen&amp;author=J+Xuan&amp;author=L+Couch&amp;volume=322&amp;publication_year=2014&amp;pages=78-88&amp;pmid=24865413&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R46">46. <span class="element-citation">Kurosaki M, Takagi H, Mori M. HLA-A33/B44/DR6 is highly related to intrahepatic cholestasis
induced by tiopronin. <span><span class="ref-journal">Dig Dis Sci. </span>2000;<span class="ref-vol">45</span>:1103–8.</span> [<a href="/pubmed/10877223" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Dig+Dis+Sci&amp;title=HLA-A33/B44/DR6+is+highly+related+to+intrahepatic+cholestasis
induced+by+tiopronin&amp;author=M+Kurosaki&amp;author=H+Takagi&amp;author=M+Mori&amp;volume=45&amp;publication_year=2000&amp;pages=1103-8&amp;pmid=10877223&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R47">47. <span class="element-citation">Sidney J, Peters B, Frahm N, et al.  HLA class I supertypes: a revised and updated
classification. <span><span class="ref-journal">BMC Immunol. </span>2008;<span class="ref-vol">9</span>:1.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2245908/">PMC free article</a>]</span> [<a href="/pubmed/18211710" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=BMC+Immunol&amp;title=HLA+class+I+supertypes:+a+revised+and+updated
classification&amp;author=J+Sidney&amp;author=B+Peters&amp;author=N+Frahm&amp;volume=9&amp;publication_year=2008&amp;pages=1&amp;pmid=18211710&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R48">48. <span class="element-citation">McCormack M, Alfirevic A, Bourgeois S, et al.  HLA-A*3101 and carbamazepine-induced hypersensitivity reactions
in Europeans. <span><span class="ref-journal">N Engl J Med. </span>2011;<span class="ref-vol">364</span>:1134–43.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3113609/">PMC free article</a>]</span> [<a href="/pubmed/21428769" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=HLA-A*3101+and+carbamazepine-induced+hypersensitivity+reactions
in+Europeans&amp;author=M+McCormack&amp;author=A+Alfirevic&amp;author=S+Bourgeois&amp;volume=364&amp;publication_year=2011&amp;pages=1134-43&amp;pmid=21428769&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R49">49. <span class="element-citation">Parham LR, Briley LP, Li L, et al.  Comprehensive genome-wide evaluation of lapatinib-induced liver
injury yields a single genetic signal centered on known risk allele
HLA-DRB1*07:01. <span><span class="ref-journal">Pharmacogenomics J. </span>2016;<span class="ref-vol">16</span>:180–5.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4819766/">PMC free article</a>]</span> [<a href="/pubmed/25987243" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacogenomics+J&amp;title=Comprehensive+genome-wide+evaluation+of+lapatinib-induced+liver
injury+yields+a+single+genetic+signal+centered+on+known+risk+allele
HLA-DRB1*07:01&amp;author=LR+Parham&amp;author=LP+Briley&amp;author=L+Li&amp;volume=16&amp;publication_year=2016&amp;pages=180-5&amp;pmid=25987243&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R50">50. <span class="element-citation">Monshi MM, Faulkner L, Gibson A, et al.  Human leukocyte antigen (HLA)-B*57:01-restricted activation of
drug-specific T cells provides the immunological basis for
flucloxacillin-induced liver injury. <span><span class="ref-journal">Hepatology. </span>2013;<span class="ref-vol">57</span>:727–39.</span> [<a href="/pubmed/22987284" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=Human+leukocyte+antigen+(HLA)-B*57:01-restricted+activation+of
drug-specific+T+cells+provides+the+immunological+basis+for
flucloxacillin-induced+liver+injury&amp;author=MM+Monshi&amp;author=L+Faulkner&amp;author=A+Gibson&amp;volume=57&amp;publication_year=2013&amp;pages=727-39&amp;pmid=22987284&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R51">51. <span class="element-citation">Kim SH, Saide K, Farrell J, et al.  Characterization of amoxicillin- and clavulanic acid-specific T
cells in patients with amoxicillin-clavulanate-induced liver
injury. <span><span class="ref-journal">Hepatology. </span>2015;<span class="ref-vol">62</span>:887–99.</span> [<a href="/pubmed/25998949" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=Characterization+of+amoxicillin-+and+clavulanic+acid-specific+T
cells+in+patients+with+amoxicillin-clavulanate-induced+liver
injury&amp;author=SH+Kim&amp;author=K+Saide&amp;author=J+Farrell&amp;volume=62&amp;publication_year=2015&amp;pages=887-99&amp;pmid=25998949&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R52">52. <span class="element-citation">Illing PT, Vivian JP, Dudek NL, et al.  Immune self-reactivity triggered by drug-modified HLA-peptide
repertoire. <span><span class="ref-journal">Nature. </span>2012;<span class="ref-vol">486</span>:554–8.</span> [<a href="/pubmed/22722860" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Immune+self-reactivity+triggered+by+drug-modified+HLA-peptide
repertoire&amp;author=PT+Illing&amp;author=JP+Vivian&amp;author=NL+Dudek&amp;volume=486&amp;publication_year=2012&amp;pages=554-8&amp;pmid=22722860&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R53">53. <span class="element-citation">Gamez-Diaz L, August D, Stepensky P, et al.  The extended phenotype of LPS-responsive beige-like anchor
protein (LRBA) deficiency. <span><span class="ref-journal">J Allergy Clin Immunol. </span>2016;<span class="ref-vol">137</span>:223–30.</span> [<a href="/pubmed/26768763" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Allergy+Clin+Immunol&amp;title=The+extended+phenotype+of+LPS-responsive+beige-like+anchor
protein+(LRBA)+deficiency&amp;author=L+Gamez-Diaz&amp;author=D+August&amp;author=P+Stepensky&amp;volume=137&amp;publication_year=2016&amp;pages=223-30&amp;pmid=26768763&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R54">54. <span class="element-citation">Cohen JI. Primary Immunodeficiencies Associated with EBV
Disease. <span><span class="ref-journal">Curr Top Microbiol Immunol. </span>2015;<span class="ref-vol">390</span>:241–65.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6349415/">PMC free article</a>]</span> [<a href="/pubmed/26424649" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Curr+Top+Microbiol+Immunol&amp;title=Primary+Immunodeficiencies+Associated+with+EBV
Disease&amp;author=JI+Cohen&amp;volume=390&amp;publication_year=2015&amp;pages=241-65&amp;pmid=26424649&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R55">55. <span class="element-citation">Bogaert DJ, Dullaers M, Lambrecht BN, et al.  Genes associated with common variable immunodeficiency: one
diagnosis to rule them all? <span><span class="ref-journal">J Med Genet. </span>2016</span> [<a href="/pubmed/27250108" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Med+Genet&amp;title=Genes+associated+with+common+variable+immunodeficiency:+one
diagnosis+to+rule+them+all?&amp;author=DJ+Bogaert&amp;author=M+Dullaers&amp;author=BN+Lambrecht&amp;publication_year=2016&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R56">56. <span class="element-citation">Levy E, Stolzenberg MC, Bruneau J, et al.  LRBA deficiency with autoimmunity and early onset chronic erosive
polyarthritis. <span><span class="ref-journal">Clin Immunol. </span>2016</span> [<a href="/pubmed/27057999" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Immunol&amp;title=LRBA+deficiency+with+autoimmunity+and+early+onset+chronic+erosive
polyarthritis&amp;author=E+Levy&amp;author=MC+Stolzenberg&amp;author=J+Bruneau&amp;publication_year=2016&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R57">57. <span class="element-citation">Lo B, Zhang K, Lu W, et al.  Autoimmune disease. Patients with LRBA deficiency show CTLA4 loss
and immune dysregulation responsive to abatacept therapy. <span><span class="ref-journal">Science. </span>2015;<span class="ref-vol">349</span>:436–40.</span> [<a href="/pubmed/26206937" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Autoimmune+disease.+Patients+with+LRBA+deficiency+show+CTLA4+loss
and+immune+dysregulation+responsive+to+abatacept+therapy&amp;author=B+Lo&amp;author=K+Zhang&amp;author=W+Lu&amp;volume=349&amp;publication_year=2015&amp;pages=436-40&amp;pmid=26206937&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R58">58. <span class="element-citation">Metushi IG, Hayes MA, Uetrecht J. Treatment of PD-1(-/-) mice with amodiaquine and anti-CTLA4 leads
to liver injury similar to idiosyncratic liver injury in
patients. <span><span class="ref-journal">Hepatology. </span>2015;<span class="ref-vol">61</span>:1332–42.</span> [<a href="/pubmed/25283142" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=Treatment+of+PD-1(-/-)+mice+with+amodiaquine+and+anti-CTLA4+leads
to+liver+injury+similar+to+idiosyncratic+liver+injury+in
patients&amp;author=IG+Metushi&amp;author=MA+Hayes&amp;author=J+Uetrecht&amp;volume=61&amp;publication_year=2015&amp;pages=1332-42&amp;pmid=25283142&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R59">59. <span class="element-citation">Cadwell CM, Su W, Kowalczyk AP. Cadherin tales: Regulation of cadherin function by endocytic
membrane trafficking. <span><span class="ref-journal">Traffic. </span>2016</span> [<a href="/pubmed/27624909" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Traffic&amp;title=Cadherin+tales:+Regulation+of+cadherin+function+by+endocytic
membrane+trafficking&amp;author=CM+Cadwell&amp;author=W+Su&amp;author=AP+Kowalczyk&amp;publication_year=2016&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R60">60. <span class="element-citation">Bjornsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic
liver injury post-marketing. <span><span class="ref-journal">J Hepatol. </span>2012;<span class="ref-vol">56</span>:374–80.</span> [<a href="/pubmed/21889469" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Hepatol&amp;title=Hepatotoxicity+associated+with+statins:+reports+of+idiosyncratic
liver+injury+post-marketing&amp;author=E+Bjornsson&amp;author=EI+Jacobsen&amp;author=E+Kalaitzakis&amp;volume=56&amp;publication_year=2012&amp;pages=374-80&amp;pmid=21889469&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5367948&amp;issue-id=289969&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div></div></div><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu"><ul id="ui-ncbiinpagenav-2"><li><a href="#ui-ncbiinpagenav-heading-3">Associated Data</a></li><li><a href="#idm139620996736016title">Abstract</a></li><li><a href="#S5title">Introduction</a></li><li><a href="#S6title">Materials and Methods</a></li><li><a href="#S21title">Results</a></li><li><a href="#S26title">Discussion</a></li><li><a href="#SMtitle">Supplementary Material</a></li><li><a href="#S27title">Acknowledgments</a></li><li><a href="#idm139620996328832title">Abbreviations</a></li><li><a href="#idm139620997605344title">Footnotes</a></li><li><a href="#idm139620984766304title">References</a></li></ul></div></div><!--post-content--></div>
            
            
        
            
        </div>
        <!-- Book content -->
    </div>
    
    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            
        </div>
        
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC5367948/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC5367948/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC5367948/pdf/nihms-840066.pdf">PDF (434K)</a></li> | <li><a href="#" data-citationid="PMC5367948" class="citationexporter ctxp" role="button" aria-expanded="false" aria-haspopup="true">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5367948%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook">
                             Facebook
                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5367948%2F&amp;text=Association%20of%20Liver%20Injury%20From%20Specific%20Drugs%2C%20or%20Groups%20of%20Drugs%2C%0AWith%20Polymorphisms%20in%20HLA%20and%20Other%20Genes%20in%20a%20Genome-wide%20Association%0AStudy" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter">
                             Twitter
                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5367948%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus">
                             Google+
                        </a></li></ul></div>
        
        <div id="ajax-portlets" data-pmid="28043905" data-aiid="5367948" data-aid="5367948" data-iid="289969" data-domainid="319" data-domain="nihpa" data-accid="PMC5367948" data-md5="bd3ca2998a3f9ddae19fc69ab2d9796c"><img src="/portal/portal3rc.fcgi/4018218/img/3631476" alt="Loading..." align="absmiddle"> Loading portlets...</div>
                
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script>
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>



<div id="body-link-poppers"></div>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-11-20T15:34:00-05:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=portal103&amp;ncbi_phid=CE8AFBBBDD59E73100000000030601C3&amp;ncbi_session=CE8C6010DD4F8B31_0740SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5367948%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        <div class="ui-ncbiautocomplete-holder shadow ui-ncbiautocomplete-holder-clearfix" aria-live="assertive" style="display: none; top: 68.1px; left: 377.2px; width: 670px; z-index: 1001;"><ul class="ui-ncbiautocomplete-options" role="listbox" aria-activedescendant="term"></ul><div class="ui-ncbiautocomplete-actions shadow" style="display: block;"><a class="ui-ncbiautocomplete-link-pref" style="display: none;">Preferences</a><a href="#" class="ui-ncbiautocomplete-link-off ui-ncbiautocomplete-link-pref-right" style="display: block;">Turn off</a></div></div><div style="display: none; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic">External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div></div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=nihpa&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC5367948/&amp;ncbi_app=pmc" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C6010DD4F8B31_0740SID /projects/PMC/PMCViewer@4.46 portal103 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script>
<div class="ui-dialog ui-widget ui-widget-content ui-corner-all ui-front" style="display: none;" tabindex="-1" role="dialog" aria-describedby="epubDialog" aria-labelledby="ui-id-1"><div class="ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix"><span id="ui-id-1" class="ui-dialog-title">Making articles easier to read in PMC</span><button type="button" class="ui-button ui-widget ui-state-default ui-corner-all ui-button-icon-only ui-dialog-titlebar-close" role="button" title="Close"><span class="ui-button-icon-primary ui-icon ui-icon-closethick"></span><span class="ui-button-text">Close</span></button></div><div id="epubDialog" style="display: block;" class="ui-dialog-content ui-widget-content">  <p>We are experimenting with display styles that make it easier to read articles     in PMC.     Our first effort uses eBook readers, which have several "ease of reading"     features already built in.</p>  <p>These PMC articles are best viewed in the <em>iBooks     reader</em>. You may notice problems with the display of certain parts of an article     in other eReaders.</p>  <div class="ui-dialog-buttonpane ui-widget-content ui-helper-clearfix"><button id="cancelEpub" class="ui-state-default ui-corner-all">Cancel</button><button id="downloadEpub" style="float: left" class="ui-state-default ui-corner-all">Download article</button></div>          </div></div></body></html>